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ABSTRACT

Identification and Characterization of Genetic Factors Involved in Candida-Bacterial
Interactions

by

Sean J. Fox

Throughout existence, fungi and bacteria have long shared ecological niches and thus
engage in numerous interactions to mutually enhance survival or antagonistically gain
competitive advantages. Of importance to human health are those interactions that
involve bacteria with the opportunistic fungi, Candida albicans. An important virulence
factor of C. albicans is the ability to control morphology, which allows the transition
between yeast, pseudohyphal, and hyphal phenotypes. Morphological control in C.
albicans is governed by quorum sensing and the secreted autoregulatory molecule
farnesol. Quorum sensing allows individual cells to sense the environment and respond
as a group. Bacteria also use quorum sensing to communicate and control virulence.
Despite their abundance in nature, very little is known about the interactions of C.
albicans with bacteria on a genetic and molecular level. The objective of our research is
to identify the genetic elements involved in C. albicans-bacterial interactions and
characterize the genes that may participate in these relationships. To accomplish this,
we screened a C. albicans mutant library for the ability to filament in the presence of
Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, where
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typically, these 3 bacterial species inhibit C. albicans filamentation. We identified 836
C. albicans mutants that displayed a filamentous phenotype in the presence of bacteria.
Collectively, 295 of these mutants filamented in the presence of all 3 bacterial species.
Candidates were subsequently sequenced to identify the location of the mutation and
the affected genetic element. CDR4, a putative ABC transporter, and ALS6, a putative
adhesion, were further characterized for their specific involvement in Candida-bacterial
interactions. Using a filamentation assay, cdr4 and als6 deletion strains demonstrated a
decreased response to the inhibitory effects of farnesol as well as bacterial molecules
known to inhibit the production of hyphal-filaments. Additionally, the ability of cdr4 and
als6 deletion strains to attach and form biofilms was significantly enhanced even in the
presence of farnesol and bacterial inhibitors. The results of this study contribute to the
body of knowledge involving polymicrobial interactions, and these findings may lead to
new antifungal targets for therapeutic interventions.
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CHAPTER 1
INTRODUCTION
Historically, microorganisms have been viewed as pathogens with a majority of
the medical and scientific community’s knowledge of microbes derived from pure
cultures. However, rarely in the environment and the human body does one find such a
pure culture and distinct nature of single isolated microorganisms. In fact, the human
body alone is inhabited by trillions of microbes representing thousands of species that
comprise the normal flora. These microbial communities exhibit dynamic interactions,
express a spectrum of relationships, and employ several forms of communication.
Research into polymicrobial interactions is quickly gaining interest due to the
implications of the effects on both human health and disease. However, many hurdles
remain due to the complex nature of multispecies communities. Understanding the
nature of microbial interactions, biofilm formation, alterations of drug efficacy,
phenotypic alterations, and medical implications of polymicrobial communities are
several areas of interest. Principal among these microbial relationships are fungalbacterial interactions involving the opportunistic polymorphic fungi, Candida albicans,
the most common fungal pathogen.
Candida albicans
C. albicans resides as part of the normal flora in 70% of the population and can
be isolated from the skin and gastrointestinal and genito-urinary tracts (Mavor et al.
2005; Kim and Sudbery 2011). While individuals with healthy immune systems can be
affected, such as women with recurring vaginitis, those individuals with compromised or
13

suppressed immune systems face a greater risk of C. albicans transitioning from a
commensal to deadly pathogen. These at-risk individuals include those undergoing
cancer treatment, HIV patients, extreme age (both the very young and very old),
indwelling devices, and long-term antibiotic treatment (Giri and Kindo 2012). C.
albicans causes candidiasis of the tissue and candidemia of the bloodstream (Giri and
Kindo 2012). Interestingly, Nucci et al. (2001) examined the origins of candidemia and
provided a strong case for the involvement of the human gut’s own Candida population
as the source. Prevalence of C. albicans, especially in the healthcare setting, is
staggering as C. albicans is the fourth most common organism involved in nosocomial
blood stream infections, the third most commonly isolated organism of catheter related
infections, and the second most common opportunistic microorganism of HIV infected
patients (Crump and Collignon 2000; Wisplinghoff et al. 2004; Ramage et al. 2006;
Hamza et al. 2008; Kim and Sudbery 2011;). Mortality of C. albicans infections,
particularly when involving the bloodstream, can reach as high as 35-40%, especially
for patients in an intensive care unit setting (Gudlaugsson et al. 2003).
C. albicans has numerous virulence factors at its disposal to enhance survival in
the host for both localized and systemic infections. These include diverse adhesins, the
ability to form biofilms (both monospecies and polymicrobial), degradative enzymes,
numerous drug resistance mechanisms, and lastly, which has garnered much research
of late, the ability to change morphology (Cowen et al. 2002; Sundstrom 2002; Ramage
et al. 2005; Schaller et al. 2005). A number of C. albicans virulence factors can be
linked to specific morphological states. For example, the secreted aspartyl proteinases
(SAP) are a group of enzymes responsible for degradation of human proteins. While
14

Sap1p, Sap2p, and Sap3p are expressed by yeast cells, Sap4p and Sap6p are
associated with the hyphal form (Naglik et al. 2003). Likewise, adhesions are also
associated with different morphologies. Agglutin-like sequence protein (Als3p) and
hyphal wall protein (Hwp1p) are hyphal specific, yeast wall protein (Ywp1p) is yeast
specific, and enhanced adhesion to polystyrene protein (Eap1p) is expressed by both
morphological forms (Nobile and Mitchell 2006; Li et al. 2007; Liu and Filler 2011).
Moreover, mature biofilm formation and some instances of drug resistance depend
upon the ability of C. albicans to transition from yeast to hyphae (Baillie and Douglas
1999). Thus, the virulence attribute of polymorphism appears to be an ideal target for
C. albicans research.
Polymorphic Nature of C. albicans
C. albicans infections and overall virulence comprises the reversible transition
between unicellular yeast, pseudohyphal, and hyphal forms. A variety of environmental
factors shape morphological transition and can be induced in the laboratory via
numerous controllable conditions. Some of the more potent inducers of hyphal
formation are serum, pH (neutral), temperature (37°C), and the type of media used,
such as M199, a synthetic tissue culture media (Han et al. 2011). Each morphological
state is associated with specific roles in C. albicans pathogenesis and to be effectively
virulent, it is essential for C. albicans to interconvert between morphologies (Sudbery et
al. 2011). The yeast morphology is necessary for initial attachment, colonization, and
dissemination of the organism at sites of infection (Saville et al. 2003). The hyphal form
has the crucial responsibilities of host cell and tissue invasion as well as immune
evasion (Shareck and Belhumeur 2011; Brand 2012;). Infection of tissue and access to
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the bloodstream requires the hyphal form to breach epithelial cells and their associated
barriers to enter critical areas of the human body (Grubb et al. 2008, Wachtler et al.
2012). Hyphae are also important in escape from host immune cells, specifically
macrophages (Lorenz et al. 2004). When C. albicans is locked into one morphological
form, virulence is attenuated. For example, using a mouse model, treatment of
systemic candidiasis was successful by inhibiting filamentation using a Candida strain
engineered to alter its morphology based on the presence of doxycycline (Saville et al.
2006). Finally, C. albicans is part of the normal flora of most immunologically
competent individuals and the host immune system has adapted to recognize cues from
C. albicans when it shifts from a commensal to a pathogen. Moyes et al. (2010)
observed that the yeast form adheres to host cells and is tolerated by the immune
system, while a switch to hyphal morphology alerts and elicits a response from immune
cells. This is clear evidence that morphogenesis is important for C. albicans to colonize
and infect the host.
Signaling Pathways of Morphogenesis
C. albicans regulates its morphology in response to numerous cues perceived
from the varied habitats in which it resides. These cues include temperature, nitrogen
levels, serum, amino acid availability, pH, nutrient limitations, serum, quorum sensing,
and solid matrixes (Sudbery 2011). Each environmental cue has an associated
membrane detector or directly interacts with a genetic factor of the respective signaling
system. For instance, temperature (37°C) is sensed by the heat shock protein Hsp90p,
amino acids are detected by the G-protein coupled receptor (Gpr1p), nitrogen levels are
detected via the ammonium permease (Mep2p), and CO2 levels are detected through
16

the carbonic anhydrase (Nce103p) (Biswas and Morschhauser 2005; Maiden et al.
2005; Shapiro et al. 2009; Klengel et al. 2013). In contrast, embedded agar matrix,
serum, and QS molecules act directly upon a component of their respective signaling
cascade (Sudbery 2011). Consequently, with the varied cues that C. albicans responds
to, there are a number of signaling pathways that have been identified to control
morphology. Five of the most studied pathways include the cyclic AMP-protein kinase A
(cAMP-PKA) pathway, the mitogen-activated protein kinase (MAPK) pathway, the pH
pathway, the embedded matrix pathway, and a negative regulation of hyphae pathway.
Each of the pathways also involve a variety of positive transcriptional regulators (Efg1p,
Cph1p, Czf1p) and negative transcriptional regulators (Tup1p, Nrg1p, Rfg1p) of hyphal
development (Sudbery 2011).
Of the known pathways, the most studied and most important is the cAMP-PKA
pathway. This pathway controls, directly or indirectly, a number of the signals
generated from environmental cues such as temperature, amino acids, CO2, serum,
and nitrogen (Sudbery 2011). Activation of cAMP-PKA occurs via the adenyl cyclase,
Cyr1p, which funnels the signals from multiple environment cues (Rocha et al. 2001).
Cyr1p can be activated via a Ras1p dependent or independent manner. Ras1p is a
membrane associated GTPase that upon physical association with Cyr1p causes an
increase in cAMP levels (Biswas et al. 2007). Ras1p dependent activation of Cyr1p is
through serum, nitrogen, and temperature cues. In contrast, independent activation of
Cyr1p can occur through serum associated bacterial peptidoglycan, amino acid, and
CO2 cues by directly associating with Cyr1p (Biswas et al. 2007). The ultimate target of
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the cAMP-PKA pathway is the transcriptional factor Efg1p, which is the foremost
positive regulator of hyphal development (Sohn et al. 2003).
The second pathway, MAPK, is also involved in signal response to temperature,
nitrogen, and serum (Sudbery 2011). MAPK signaling is via Ras1p and the
transcriptional target is the positive regulator Cph1p (Monge et al. 2006). While the
cAMP-PKA and MAPK pathways have a number of shared environmental triggers, as
well as genetic signaling components, the pH pathway only shares the target
transcriptional regulator Efg1p (Sudbery 2011). In this pathway Rim21p, a membrane
associated sensor, detects the pH of the environment and causes the proteolytic
cleavage of the transcriptional regulator Rim101p that targets genes associated with
hyphal development (Biswas et al. 2007). Rim101p, in turn, bypasses the signaling of
the cAMP-PKA pathway and directly regulates Efg1p (Biswas et al. 2007). The fourth
pathway, embedded matrix, involves the hyphal induction pathways associated with C.
albicans when cells become embedded into agar. This pathway is also independent of
the cAMP-PKA and MAPK pathways and the transcriptional target is CSF1 (Sudbery
2011). The last pathway, negative regulation, is associated with 3 different
transcriptional repressors of hyphal development. Tup1p is the dominant repressor and
has been implicated in the regulation of morphogenesis involving quorum sensing
(Braun 1997; Kebaara et al. 2008). The other 2 transcriptional factors, Nrg1p and
Rfg1p, seem to work in tandem with Tup1p and even recruit Tup1p when repressing
filamentation (Kadosh and Johnson 2001; Murad et al. 2001). Thus, the events
controlling C. albicans morphogenesis encompass a variety of environmental triggers
that appear to regulate morphogenesis through multiple routes.
18

Quorum Sensing
Microorganisms are highly adaptable and, through close contact in shared
environments, have developed means of communicating with each other. Cell to cell
communication in the microbial world is a complex network that spans intraspecies,
interspecies, and inter-kingdom interactions involving prokaryotic and eukaryotic
microbes. The term quorum sensing (QS) has been used to describe this
communication process involving small secreted molecules. QS is based on 2 main
components, quorum sensing molecules (QSMs) and the increase in cell density of a
population. Microorganisms secrete QSMs into the environment and, as the cell density
of the population increases, so do the concentration of QSMs. Eventually, the
population reaches a tipping point where the QSMs reach a threshold concentration.
Once this threshold is met, the population can operate as a ‘quorum’ and activate signal
transduction pathways to activate or repress genes responsible for a variety of
biological functions, including motility, bioluminescence, morphology, and virulence
(Antunes et al. 2010). Certain criteria should be applied to differentiate QSMs from
other molecules a microorganism emits. These criteria include extracellular
secretion/accrual in response to a certain change (such as cell growth), a dedicated
receptor that recognizes the QSM, and a response by the microorganism that the QSM
induces (Atkinson and Williams 2009). While QS has been studied extensively in single
species systems, relatively little is known about the cross-kingdom communication of
QS and QSMs in the polymicrobial setting of prokaryotic-eukaryotic communities.
Quorum Sensing in C. albicans. The discovery of QS in C. albicans and the
QSM farnesol was the first documented example found in eukaryotes (Hornby et al.
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2001). The notion that morphology may be controlled by QSMs was observed when C.
albicans cells were added to spent culture media, which induced this morphological
change (Hornby et al. 2001). The C. albicans QSM farnesol acts in a density
dependent manner. At concentrations below 1x106 cells/ml, C. albicans typically display
the hyphal morphology (Kruppa 2009). However, as the cell density increases above
this concentration, there is an accumulation of farnesol molecules in the environment
and the cells revert to the yeast morphology (Hornby et al. 2001). Farnesol, at
concentrations ranging from 10-250 µM, has the ability to inhibit the yeast to hyphal
transition, even when C. albicans is grown under hyphal inducing conditions (Kruppa et
al. 2004). Farnesol at this range inhibits biofilm formation but does not affect C.
albicans growth rate or block elongation of pre-existing hyphae (Hornby et al. 2001;
Ramage et al. 2002). C. albicans cells exposed to farnesol have decreased expression
of hyphal formation associated genes, while also exhibiting an increase in drug and
oxidative stress resistance (Cao et al. 2005; Enjalbert and Whiteway 2005; Westwater
et al. 2005). A number of other molecules that C. albicans secretes have been
suggested to be additional QSMs. However, most of these molecules either are not
relevant at density dependent levels or produce only a small fraction of the change that
farnesol exerts. For example, farnesoic acid was originally reported to be a QSM and
inhibitor of C. albicans morphogenesis but was determined to be found in only one
particular strain (Oh et al. 2001; Hornby and Nickerson 2004). Two other molecules,
tryptophol and phenylethyl alcohol, were observed to have “autoantibiotic” properties by
reducing filamentation in C. albicans (Lingappa et al. 1969). However, the
concentrations of the 2 molecules proved to be extremely high to mediate morphological
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control over C. albicans (Lingappa et al. 1969). Conversely, another QSM, tyrosol, has
the opposite effect of farnesol. Tyrosol can induce hyphal production in C. albicans,
which shortens the amount of time required to induce germ tube formation of yeast cells
(Chen et al. 2004). This induction of hyphae can also affect the early stages of biofilm
formation by increasing biomass (Alem et al. 2006). However, when added exogenously
at the same time as farnesol, farnesol mutes the pro-hyphae effects of tyrosol (Alem et
al. 2006). Clearly, C. albicans secretes a number of factors that control its morphology,
but farnesol is the primary regulator of the yeast to hyphal transition.
Our understanding of QS signaling pathways in C. albicans is relatively limited
and the receptor involved in farnesol response is unknown. Five elements have been
implicated as playing roles in C. albicans signaling and regulation of QS response.
These include Ras1p, Tup1p, Cph1p, Hst7p, and Chk1p (Kruppa 2009). Ras1p is a
major regulator of farnesol induced response by signaling through either the cAMP-PKA
or MAPK pathways that govern hyphal production (Leberer et al. 2001). Tup1p, a
transcriptional regulator, negatively regulates hyphae production in C. albicans (Braun
1997). Upon exposure to farnesol, TUP1 mRNA and protein levels are induced
(Kebaara et al. 2008). Cph1p and Hst7p are integral parts of the MAPK signaling
cascade and mRNA of both genes are decreased in C. albicans cells that are exposed
to farnesol (Sato et al. 2004). MAPK signaling is heavily involved in the regulation of
filamentation, especially in response to numerous environmental stimuli (Shapiro et al.
2011). Lastly, Chk1p is a histidine kinase involved in cell wall biosynthesis via a 2component signaling system (Kruppa et al. 2004). CHK1 mutants exposed to farnesol
are not responsive to the inhibitory effects and grow mainly as hyphae (Kruppa et al.
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2004). It is not entirely clear at this point how farnesol response signals through these
multiple genetic elements.
Quorum Sensing in Bacteria. Bacterial QS and QSMs were first described in the
bioluminescence of Vibrio fischeri and its mutualistic relationship with the bobtail squid
(Kempner and Hanson 1968). Since this initial discovery, the process of QS and the
components that constitute the machinery of QS have been described in numerous
bacterial species. QS in bacteria can be divided into 3 different classes. The first class
belongs to Gram-positive bacteria, such as S. aureus, which involves small
autoinducing peptides (AIPs) as QSMs, coupled with an accessory gene regulator (agr)
2-component regulatory mechanism (Antunes et al. 2010). The agr locus encodes
agrA, agrB, agrC, and agrD (Antunes et al. 2010). AgrD encodes the immature AIP,
which is cleaved and secreted by the membrane bound AgrBp (Qiu et al. 2005). When
extracellular levels of AIP reach a sufficient level, the membrane associated AgrCp
binds AIP and activates AgrAp through phosphorylation of ArgCp (Lina et al. 1998).
The agrA protein then binds to target genes and induces expression of over 70 different
genes of which 23 are associated with virulence factors (Antunes et al. 2010).
The second class belongs to Gram-negative bacteria, such as P. aeruginosa,
and involves homoserine lactone molecules (HSL) coupled with a LasI/LasR system
(Antunes et al. 2010). The LasI component makes HSL that is able to diffuse freely
across the cell membrane (Antunes et al. 2010). HSL molecules engage the LasR
component, which binds to the promoter of the appropriate gene and initiates
transcription (Antunes et al. 2010). In actuality, P. aeruginosa has 3 different QS
systems as well as an “orphan receptor” for QS. In addition to the LasI/LasR QS
22

system there is a Rhl/C4HSL QS system that works much like the 3OC12HSL/Las
system (Antunes et al. 2010). Finally, in the Pseudomonas quinolone signal system
(PQS) the pqsABCD operon is involved in the genesis of 2-heptyl-4-quinolone (HHQ),
the precursor of PQS (Diggle et al. 2006). The PQS system links the Las system to the
Rhl system that is under the control of the Las to regulate virulence (Diggle et al. 2006;
Dekimpe and Deziel 2009).
Finally, the third class belongs to both Gram-positive and Gram-negative bacteria
and is considered an interspecies QS communication pathway. This class involves
Autoinducer-2 (AI2) as the signaling molecule coupled with a LuxS/LuxR system
(Antunes et al. 2010). AI2 is synthesized by LuxS and this system has been identified
in more than 55 bacterial species (De Keersmaecker et al. 2006). Even bacterial
species that do not secrete AI2 still have the ability to respond to AI2, which lends
credence to the notion that this is a universal molecule of bacterial communication
(Dufour and Rao 2011).
Drug Treatment and Resistance
C. albicans has relatively few therapeutic treatments compared to the number of
antibiotics available for bacterial infections. There are 4 main classes of drug
targets/treatments for C. albicans: the azoles, polyenes, fluorocytosines, and
echinocandins. Each drug target/treatment has benefits and drawbacks. The azoles,
which include fluconazole, target the membrane by inhibiting an enzyme essential in
ergosterol biosynthesis (Tobudic et al. 2010). These drugs are fungistatic as they inhibit
growth and do not actually kill C. albicans. In cases of resistance to azoles, there are
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several mechanisms, which include overexpression of lanosterol, an intermediate in the
ergosterol pathway, as well as mutations that affect the binding of azoles to their targets
(Cannon et al. 2007). Unfortunately, because azoles are fungistatic, this can lead to
selective survival that increase the chances of resistance (Cannon et al. 2007). The
polyenes, which include nystatin, target and bind to ergosterol, allowing pore formation
in the membrane and reduces the integrity of the cell (Cannon et al. 2007). Polyenes
are fungicidal and resistance is rare making them very useful in the treatment of
systemic Candida infections (Cannon et al. 2007). When resistance occurs, it is due to
a reduction of ergosterol in the plasma membrane (Cannon et al. 2007). The
disadvantage of polyenes is host toxicity, especially during prolonged use, due to the
similarity of ergosterol to human cholesterol (Shapiro et al. 2011). The echinocandins,
including caspofungin, are the newest of the drug classes and inhibit cell wall
biosynthesis, thus causing a loss in cell wall integrity (Shapiro et al. 2011). Less is
known about the long-term effects of echinocandins and there have been documented
instances of drug resistance (Shapiro et al. 2011). In all 3 drug classes, drug resistance
is associated with modulation of the drug target, increase in drug exporters, acquired
responses to stress, and biofilm formation (Cannon et al. 2007). In respect to
morphology, drug resistance and mature biofilm growth that exhibit increased drug
resistance require the ability to form both yeast and hyphal morphologies (Chandra et
al. 2001). The harmful side effects of current drugs, the increase in resistance to
current treatments, and the lack of new antifungal targets demonstrate a need for novel
applications of known virulence inhibitors for C. albicans. Thus, the polymorphic nature
of C. albicans seems an attractive candidate. Targeting and controlling virulence factors
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rather than eradicating and selecting for drug resistance may be an ideal method of
combating C. albicans, especially because it is part of the normal flora.
Candida-Bacterial Interactions
The interaction of Candida with bacteria is quickly becoming an important area of
medical research for a number of reasons. C. albicans is normally a commensal
organism until conditions change that benefits its growth and pathogenicity. There is
mounting evidence that Candida infections spawn from a person’s own normal flora
(Wargo and Hogan 2006). Research has implicated that the normal flora bacterial
members, in addition to many other beneficial attributes, keep the commensal Candida
in check (Mason et al. 2012). When imbalances occur, as in antibiotic treatment, the
imbalance tips the scale in favor of Candida overgrowth to transition from normal flora to
pathogenic (Mason et al. 2012). Secondly, Candida-bacterial interactions can be
harmful or beneficial to the host and understanding these interactions could aid in
human health. Beneficial interactions include chemical and physical interactions that
indicate bacteria can inhibit Candida virulence factors and suppress overgrowth (Boris
and Barbés 2000). Harmful interactions include increased mortality from polymicrobial
infections and Candida-bacterial biofilms that intensify persistence and severity of
infection as well as increased drug resistance (Carlson 1982; Harriott and Noverr 2009;
Peleg et al. 2010). Lastly, the understanding of polymicrobial interactions is, at best, in
its infancy. There exists a great potential for the development of new antifungals and
antimicrobials derived from the uncharacterized world of Candida-bacterial interactions.
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Sites of Candida-Bacterial Interactions
Systemic Infections. Perhaps the most dangerous form of polymicrobial
interaction to human health involves bloodstream infections (BSI). Once
microorganisms gain access to the bloodstream, dissemination and infection can
manifest in practically any part of the human body. C. albicans is the fourth most
common causative agent of nosocomial BSIs and 27% to 56% of C. albicans BSIs are
polymicrobial (Wisplinghoff et al. 2004; Klotz et al. 2007). In a study of Candida BSI
patients, the most commonly isolated bacterial species with Candida was S. aureus
(20%), while P. aeruginosa (8%), and E. coli (4%) were also coisolated (Klotz et al.
2007). Patients with bacteremia and candidemia have reduced survival rates compared
to those with candidemia alone (Dyess et al. 1985).
Burn Wounds. A breach in the skin barrier is an example of trauma that can
leave an individual at risk for microbial infections. The principal bacterial species found
in burns include Klebsiella, Pseudomonas, and Staphylococcus (Gupta et al. 2005). As
the number of bacterial species present in the burn wound increases, the presence of
Candida decreases, suggesting an antagonistic relationship in this setting (Gupta et al.
2005). Pseudomonas and C. albicans are almost never co-isolated in burn wounds
(Gupta et al. 2005). This particular observation adds to the continuing theme of
antagonism between P. aeruginosa and C. albicans.
Lung/Pulmonary Tract. Pseudomonas, Staphylococcus, and Candida species
are 3 of the most common agents associated with ventilator-associated pneumonia
(VAP) (Adair et al.1999). Patients with mechanical ventilation who have colonization of
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Candida in the respiratory tract have an increased risk of Pseudomonas VAP (Azoulay
et al. 2006). Ader et al. highlighted this important association as treatment of Candida
colonization of the respiratory tract with antifungals reduces the risk of Pseudomonas
associated VAP (Ader et al. 2008). C. albicans co-infections may also impair the host
immune system’s ability to deal with Pseudomonas VAP (Roux et al. 2009). These
observations suggest that Candida-Pseudomonas interactions in burn wounds and VAP
are fundamentally different.
While Candida can be found in the lungs of healthy individuals, patients with
cystic fibrosis (CF) provide microorganisms an ideal habitat where Candida-bacterial
interactions appear abundant. A study of the microbial populations of the sputa of
patients with CF found that C. albicans was present in 78% of the patients (Valenza et
al. 2008). Bacterial colonizers included S. aureus (63%), P. aeruginosa (50%), and E.
coli (5%) (Valenza et al. 2008). The population of microbes in the CF lung changes
over time, with S. aureus associated with young children and P. aeruginosa in 80% of
CF lungs of people in their 20s (Hauser et al. 2011). This association with P.
aeruginosa also resulted in a decline in health (Hauser et al. 2011). C. albicans
colonization in CF patients is best predicted by the cocolonization by P. aeruginosa, and
this cocolonization between the 2 leads to increased exacerbation of symptoms
(Chotirmall et al. 2010).
The Oral Cavity. Oral colonization and infections are highly polymicrobial in
nature. In a study of patients with atrophic denture stomatitis, 78% of patients had
coinfections with both S. aureus and C. albicans (Monroy et al. 2005). In periodontal
disease there is a strong association of Staphylococcus with Candida (Cuesta et al.
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2010). Of the patients who have periodontal disease, Staphylococcus species were
found in 69.5% of the patients, while Candida species were identified in 42.7%, with the
most common species being S. aureus and C. albicans (Cuesta et al. 2010). In dental
prosthesis wearers, C. albicans can be isolated from 86% and S. aureus was found in
84% of patients with atrophic denture stomatitis (Monroy et al. 2005).
Vaginal Infections. Normal flora bacteria play a pivotal role in preventing C.
albicans vaginal infections. An estimated 75% of women will experience at least one
vaginal infection, with about 5-10% of women having recurrent vaginal candidiasis
(Sobel 1988). Lactobacillus species, which constitute a majority of the vaginal
microbiome, have been shown to have inhibitory effects on Candida and can aid in
preventing Candida infections. Antibiotic use disrupts this protection by destroying the
bacterial biome allowing Candida overgrowth (Noverr and Huffnagle 2004; Strus et al.
2005). Fluconazole treatment in conjunction with probiotic use of Lactobacillus was
found to aid in the treatment of vaginal candidiasis (Martinez, Franceschini et al. 2009).
In addition, Lactobacillus has been shown to reduce the ability of C. albicans to adhere
to and infect tissue (Martinez, Seney, et al. 2009).
Candida Biofilms
C. albicans biofilm formation can be divided into stages based on time and
development. The early stage (0-2 hours) encompasses attachment and primarily
involves the yeast morphological form of C. albicans (Chandra et al. 2001). The
intermediate stage (12-30 hours) involves yeast, pseudohyphal, and immature true
hyphae, and the final phase, maturation (38-72 hours), involves yeast, pseudohyphal,
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and mature hyphae (Chandra et al. 2001). The fully mature biofilm stage has 3D
architecture, channels for fluid movement, and is encased in an extracellular matrix
(Ramage, Martínez, et al. 2006). Finally, the dissemination stage results in the release
of yeast from terminal hyphae of the mature biofilm into the environment (Uppuluri et al.
2010). Morphological transition is important for the development of fully mature C.
albicans biofilms. Wild type strains of C. albicans form a normal robust biofilm with a
thin yeast foundation layer and thick upper hyphal layers (Baillie and Douglas 1999).
Conversely, a mutant locked in the yeast morphology could only form a yeast base
layer, while a mutant locked into the hyphal morphology formed only an outer hyphal
layer (Baillie and Douglas 1999). Additionally, the locked yeast or hyphal forms show
decreased biofilm integrity and increased antifungal drug sensitivity (Baillie and Douglas
1999).
Candida biofilms play a significant role in nosocomial infections associated with
implanted devices. Kojic et al. (2004) identified nosocomial agents associated with
commonly implanted devices. Candida, as the causative agent, correlated with
vascular catheters (10%), prosthetic valves (10%), ventricular assist devices (28-66%),
ventriculoperitoneal shunts (6-15%), and urinary catheters (10-30%) (Kojic and
Darouiche 2004). A second benefit of biofilms is an increase in antifungal drug
resistance. Fluconazole resistance in biofilms can be up to 400 times that of planktonic
cells, with the MIC of fluconazole 128 times higher in biofilms than in planktonic cells
(Seneviratne et al. 2008). This increased resistance can also be found with other
azoles and amphotericin B used to treat Candida infections (Hawser and Douglas
1995). Lastly, Candida-bacterial mixed biofilms have numerous benefits to the
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microorganisms involved including increased attachment opportunities, nutritional
needs, stability, drug resistance, and protection from host immune defense (Adam et al.
2002; Bamford et al. 2009; Harriott and Noverr 2009; Shirtliff et al. 2009). For example,
S. aureus forms poor biofilms, but when mixed with C. albicans can associate with
hyphae and form robust biofilms (Harriott and Noverr 2009). Additionally, P. aeruginosa
use C. albicans biofilms to establish infection by attaching to the hyphae form and use
them as a scaffold to form biofilms. Whether as monospecies or polyspecies, biofilms
have an enormous impact on human health with 65% of human infections attributed to
biofilms (Li and Tian 2012).
Candida-Bacterial Physical Interactions
Candida and E. coli. The physical interaction and type of relationship E. coli and
C. albicans share vary depending on the aspect being examined. In general, E. coli
seems to have a suppressive effect on C. albicans growth. E. coli inhibits C. albicans
germ tube formation, but delineation of this effect, whether it be mediated by physical
interactions, chemical interactions, or a combination of the two, has not been
substantially examined thus far (Nair et al. 2001). Studies involving the physical
interactions, particularly attachment, have produced conflicting results. For example,
when using human cells, preincubation of E. coli significantly increased the number of
C. albicans cells that were able to attach to human cells and it was hypothesized that E.
coli fimbriae participated in this process (Makrides, 1983). The same E. coli strain was
also used in a separate study and showed an increase in C. albicans attachment to
abiotic surfaces (Nair and Samaranayake 1996a). Under microscopic observation, E.
coli cells were reported to act as attachment sites for the yeast form of C. albicans (Nair
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and Samaranayake 1996a; Nair and Samaranayake 1996b). However, there was a
decrease in overall C. albicans attachment when epithelial cells were preincubated with
E. coli (Nair and Samaranayake 1996b). Conversely, preincubation of abiotic surfaces
with nonpathogenic E. coli inhibited attachment of C. albicans, but it is unknown
whether this is due to E. coli out competing C. albicans for space or due to a secreted
factor (Trautner et al. 2010). In a biofilm model, E. coli growth is increased when cocultured with C. albicans, compared to the biofilm mass of E. coli alone (Thein et al.
2007). There is a negative effect with a decrease in viable cell mass of C. albicans as
the concentration of E. coli increased (Thein et al. 2007). This study also found that
after 48 hours, C. albicans blastospores and a majority of hyphae were nonviable, but
E. coli remained viable in dual species biofilms (Thein et al. 2007). These results
indicate that the interactions between E. coli and C. albicans vary depending upon a
series of factors such as which microorganism is in greatest concentration, which
attaches first, and how the relationship evolves over time.
Candida and P. aeruginosa. Arguably, the majority of research into Candidabacterial relationships has centered on the interactions of C. albicans with P.
aeruginosa, which seem to have an antagonistic relationship. Hogan et al. found that
when coincubated P. aeruginosa was able to attach to, form biofilms on, and ultimately
kill C. albicans hyphae (Hogan and Kolter 2002). In contrast, P. aeruginosa was unable
to attach to yeast cells, which retain their viability (Hogan and Kolter 2002).
Subsequently, a number of factors were identified that were required for P. aeruginosa
interactions with C. albicans hyphae (see Table 1.1). Type IV pili of P. aeruginosa
appear necessary for physical interactions with C. albicans, as type IV pili mutants are
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attenuated in their attachment to hyphae and have delayed killing time (Hogan and
Kolter 2002). Additionally, the presence of bacteria was required for the killing of C.
albicans hyphae, whereas bacterial media alone did not have this effect (Hogan and
Kolter 2002). However, another study showed that cell free bacterial media alone can
kill hyphae but not as effectively as live bacteria (Brand et al. 2008).
Another factor involved in the physical interaction and killing by P. aeruginosa is
the glycosylation status of the C. albicans cell wall (Brand et al. 2008). C. albicans
strains that have defects in O-linked glycosylation were more susceptible to P.
aeruginosa contact mediated cell death, suggesting that cell wall glycans play a role in
attachment as well as cell viability (Brand et al. 2008). Cell death may also be linked to
attachment. Brand et al. found that C. albicans cell lysis occurs at points of P.
aeruginosa microcolony attachment (Brand et al. 2008). This suggests that contact
dependent factors play a role in the antagonistic relationship of P. aeruginosa and C.
albicans. In mixed Candida-Pseudomonas biofilms, competitive attachment is
prevalent. In a study of attachment and biofilm growth in mixed biofilms, the ability to
produce glycocalyx affected Candida-Pseudomonas interactions (El-Azizi et al. 2004).
Glycocalyx deficient P. aeruginosa biofilms reduced the attachment and biofilm growth
of C. albicans, while glycocalyx positive P. aeruginosa biofilms increased C. albicans
attachment (El-Azizi et al. 2004). Conversely, C. albicans preformed biofilms enhanced
the adhesion and biofilm growth of nonglycocalyx producing P. aeruginosa (El-Azizi et
al. 2004). When bacteria and C. albicans were added simultaneously, there was a
decrease in C. albicans attachment despite the glycocalyx status of the P. aeruginosa
(El-Azizi et al. 2004). The antagonistic relationship between C. albicans and P.
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aeruginosa can also be seen over the course of biofilm growth. P. aeruginosa exudes a
suppressive effect on C. albicans during the attachment phase (57% reduction),
maturation phase (67% reduction), and fully mature biofilms (99% reduction) (Bandara
et al. 2010). Candida-Pseudomonas interactions continue to be the most studied
polymicrobial interactions due to their opposing effects upon each other and serve as a
template for eukaryotic-prokaryotic relationships.
Candida and S. aureus. C. albicans and S. aureus appear to have a mutualistic
relationship, with S. aureus being the third most common microorganism coisolated in
polymicrobial C. albicans bloodstream infections (Klotz et al. 2007). This synergism and
accompanying physical interactions are best observed in mixed Candida-S. aureus
biofilms. S. aureus preferentially associates and forms colonies on hyphae without
harming the viability of hyphae as with P. aeruginosa coculture (Harriott and Noverr
2009; Harriott and Noverr 2010; Peters et al. 2010). C. albicans also confers the ability
of S. aureus to form biofilms in serum, where typically it cannot, while also protecting S.
aureus from antibiotics (Harriott and Noverr 2009). It is hypothesized that C. albicans
encases S. aureus in an extracellular matrix, thereby obstructing the effects of
antibiotics on the bacteria (Harriott and Noverr 2009). S. aureus attachment is
strongest at the tip and middle of C. albicans hyphae with weaker attachment to S.
aureus to yeast cells (Ovchinnikova et al. 2012). Using mutants deficient in hyphal
production, it was shown that morphogenesis is instrumental in the ability of S. aureus
to form mixed biofilms with C. albicans (Harriott and Noverr 2010). Only mutants that
have the ability to attach to abiotic surfaces can increase antibiotic resistance of S.
aureus (Harriott and Noverr 2010). Using atomic force microscopy in conjunction with
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C. albicans mutants, Peters et al. found that Als3p proved to be a significant player in
the attachment of C. albicans to S. aureus (see Table 1.1) (Peters et al. 2012). The
expression of Als3p in S. cerevisiae allowed the binding of S. aureus, to which it
normally cannot attach (Peters et al. 2012). The most interesting finding involving
physical interactions of C. albicans and S. aureus is the synergistic tissue invasion of
coinfections. S. aureus, which normally cannot invade tissue, appears to use C.
albicans hyphae to gain tissue access. In murine tongues it was shown that S. aureus
could only penetrate the tissue when attached to the hyphal form of C. albicans and
abolishing C. albicans Als3p negated this effect (Peters et al. 2012). Attachment most
likely involves other factors yet to be identified. While live C. albicans cells are not
necessary for S. aureus to form biofilms, heat inactivated or formalin exposed C.
albicans cannot support S. aureus attachment/biofilm growth, indicating additional
Candida surface components are involved (Harriott and Noverr 2010). Morphology also
plays a role in the relationship between C. albicans and S. aureus. In C. albicans
hyphal biofilms there is an upregulation of S. aureus proteins associated with
metabolism and protein synthesis (Peters et al. 2010). However, in yeast biofilms, S.
aureus induces protein expression related to cell stress response in C. albicans (Peters
et al. 2010). The factors of C. albicans morphogenesis, hyphal association, biofilm
formation, and antibiotic resistance all form new perspectives on the importance of
understanding Candida-S. aureus coinfections and the importance of understanding the
physical interactions of the 2 microorganisms.
Other Important Candida – Bacterial Interactions. Acinetobacter baumannii
inhibits C. albicans filamentation by attaching to the hyphal form, leading to the death of
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filaments, but leaves yeast cells viable (Peleg et al. 2008). An outer membrane protein,
ompA, of A. baumannii is involved in attachment to C. albicans and necessary for the
killing of hyphae (see Table 1.1) (Gaddy et al. 2009). Salmonella enterica serovar
typhimurium adheres to C. albicans filaments causing filament death (Kim and
Mylonakis 2011). In contrast to A. baumannii and S. typhimurium, Streptococcus
gordonii appears to share a mutualistic relationship with C. albicans by aiding in the
colonization of the oral cavity by promoting hyphal formation of C. albicans (Bamford et
al. 2009). There are a number of factors involved in attachment of S. gordonii to C.
albicans, including cell surface polypeptides and salivary adhesions (Holmes et al.
1996). C. albicans adhesin proteins have been shown to be required for S. gordonii
attachment, namely Als3p, Eap1p, and Hwp1p (Nobbs et al. 2010). S. gordonii SspB,
of the antigen family peptides, attaches to C. albicans Als3p (Bamford et al. 2009;
Silverman et al. 2010). S. gordonii takes up salivary proteins and displays them on their
surface that C. albicans can use for attachment (O’Sullivan et al. 2000). Another
Streptococcus species, S. mutans, uses glucosyltransferases to attach to C. albicans
(Gregoire et al. 2011). S. salivarius attaches to and covers C. albicans hyphae (Ishijima
et al. 2012).

Table 1.1 Attachment factors associated with Candida-bacterial interactions.
Attachment
Microorganism
Proposed Attachment Factors
Yeast
Hyphae
Acinetobacter
A. baumannii: ompA
Limited
Yes
baumannii
Escherichia
E. coli: Unknown (fimbriae?)
Yes
?
coli
P. aeruginosa: Unknown (pili?)
Pseudomonas
C. albicans: Unknown
No
Yes
aeruginosa
(Glycoproteins?)
Salmonella
S. enterica: sopB
Limited
Yes
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Reference
(Gaddy et al. 2009)
(Makrides, 1983,
Microbios)
(Hogan and Kolter
2002; Brand et al.
2008)
(Kim and Mylonakis

Table 1.1 (continued)
typhimurium
Staphylococcus
aureus
Staphylococcus
epidermidis
Streptococcus
gordonii
Streptococcus
mutans
Streptococcus
salivarius

2011)

C. albicans: Als3p

Yes

Yes

(Peters et al. 2012)

Unknown

Yes

Yes

(Adam et al. 2002)

S. gordonii: cshA, cshB, sspA,
sspB
C. albicans: Als3p, Eap1p, Hwp1p

Yes

Yes

(Bamford et al.
2009; Nobbs et l.
2010)

S. mutans: Glucosyltransferase B

Yes

?

(Gregoire et al.
2011)

Limited

Yes

(Ishijima et al.
2012)

Unknown

Candida-Bacterial Chemical Interactions
Candida and E. coli. Chemical interactions between E. coli and C. albicans
remain ill defined. E. coli is known to use the QSM AI2, but when Bandara et al.
examined the effect of AI2 on a panel of Candida species in regards to biofilm growth,
there was to be no effect on C. albicans (Bandara 2011). A relatively new QSM, AI3,
and associated QS system has been described in E. coli; however, the signaling
pathways and the resulting effects on virulence are still being investigated (Antunes et
al. 2010). It is quite possible E. coli, given its overwhelming abundance in the human
body, exudes a number of other QSMs or chemical metabolites that are unknown at this
time.
Bacterial lipopolysaccharide (LPS) may serve as a communication messenger
between bacteria and Candida. In a study of E. coli LPS on biofilm formation, there was
no effect on C. albicans biofilms, but it did have effects on other Candida species
(Bandara et al. 2009). In vivo, E. coli LPS injected into mice along with C. albicans
have a number of effects including increased virulence and increased number of cells in
tissue (Akagawa et al. 1995; Henry-Stanley et al. 2003).
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Candida and P. aeruginosa. P. aeruginosa has an arsenal of secreted molecules
and metabolites at its disposal, of which many have been shown to influence C.
albicans (see Table 1.2). Hogan et al. demonstrated that P. aeruginosa mutants with
genetic defects in secreted factor genes, such as PlcS and PlcR (phopholipase C),
PhnAB (phenazines), GacA (HSL and pyocyanin), LasR (QS molecules), RhlR (QS
molecules), and RpoN (QS response) are attenuated in the killing of C. albicans hyphae
(Hogan and Kolter 2002). Hogan et al. (2004) also identified P. aeruginosa genes
essential in inhibition of C. albicans morphological changes, including genes (lasL, lasR,
rhlL, rhlR) involved in the secretion of HSL molecules. This led to the identification of 3oxo-C12 homoserine lactone (3OC12HSL), a QSM of P. aeruginosa, as having a
significant effect on C. albicans morphology (Hogan et al. 2004). Purified 3OC12HSL
inhibits C. albicans filamentation, reverts preformed filaments back to the yeast form,
induces expression of yeast genes, and decreases expression of hyphal genes (Hogan
et al. 2004). Testing a battery of similar molecules, it was found that this effect on C.
albicans filamentation was linked to a similar 12 carbon chain structure that is shared
between 3OC12HSL and the C. albicans QSM farnesol (Hornby et al. 2001; Hogan et
al. 2004). HSL production is strain specific among P. aeruginosa and media from HSL
producing strains is able to inhibit C. albicans morphological transition, while inhibition
is not found with reduced HSL producing strains (McAlester et al. 2008). In contrast,
supernatants from P. aeruginosa HSL producers and nonproducers inhibited C.
albicans biofilm formation at the maturation phase but not at other biofilm stages
(Holcombe et al. 2010). Gene expression of C. albicans biofilms exposed to P.
aeruginosa supernatant from both HSL producing and non-HSL producing strains affect
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different genes but also regulate expression of an overlapping 238 genes (Holcombe et
al. 2010; Reen et al. 2011). HHQ, a precursor to PQS, inhibits C. albicans biofilm
formation without affecting adhesion or morphology (Reen et al. 2011). Phenazines
also reduce C. albicans viability, ability to produce hyphae, attachment, alter
metabolism, and influence biofilm formation (Morales et al. 2013). P. aeruginosa cis-2decenoic acid induces C. albicans biofilm dispersion, as well as that of many other
bacterial biofilms (Davies and Marques 2009). Pyocyanin and 1-hydroxyphenazine
inhibit C. albicans growth and pyocyanin treated C. albicans cells lack hyphal
development (Kerr et al. 1999). Taken together, the numerous molecules involved in
Candida-Pseudomonas interactions highlight the steps each microorganism will take to
gain an advantage.
Candida and S. aureus. Although S. aureus and C. albicans have a number of
intricate physical associations, particularly with the hyphal form, and are found together
in numerous areas of the human body, relatively little is known about their chemical
interactions. While S. aureus employs a peptide system of QS, to date these AIPs have
not been tested for influence on C. albicans.
Other Notable Candida-Bacterial Chemical Interactions. Acinetobacter
baumannii spent bacterial media from the stationary phase growth inhibits C. albicans
filamentation and biofilm growth but not to the same extent of live cells (Peleg et al.
2008). A. baumannii implements a LuxI autoinducer system, but mutations in LuxI do
not inhibit filamentation (Peleg et al. 2008). However, a mutant of the A. baumannii
gacS sensor kinase has reduced filament inhibition and cell death of C. albicans,
indicating secreted molecules may play a role in this process (Peleg et al. 2008).
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Xanthomonas campestris produces a diffusible signal factor (DSF), cis-11methyl-2-dodecenoic acid, that acts as a signaling molecule to control virulence (Wang
et al. 2003). DSF is similar structurally to farnesol and can inhibit the yeast to hyphal
shift in C. albicans albeit with less potency (Wang et al. 2003).
Burkholderia cenocepacia produces a signal molecule very similar to X.
campestris DSF and structurally similar to the C. albicans QSM (Zhang et al. 2011)
This signal molecule, cis-2-dodecenoic acid (BDSF), is a potent inhibitor of C. albicans
germ tube formation with stronger inhibitory effects than that of farnesol, HSL, and DSF,
(Boon et al. 2008). Zhang et al. expanded on these findings and found that BDSF is an
effective inhibitor of C. albicans biofilm formation but has limited effects on preformed
biofilms (Zhang et al. 2011). Also, BDSF greatly reduces the expression of hyphal
specific genes HWP1 and ALS3 (Zhang et al. 2011).
Enterococcus faecalis supernatant inhibits C. albicans filamentation in a
Caenorhabditis elegans model, while also inhibiting biofilm formation, but does not
seem to kill C. albicans (Cruz et al. 2013). E. faecalis uses small peptides as QSMs,
GBAP, and the Fsr QS system. GBAP does not seem to be involved, but the Fsr system
does play a role in the inhibitory effects on C. albicans (Cruz et al. 2013).
Streptococcus mutans secretes a number of molecules that have effects on C.
albicans. The first molecule shown to influence C. albicans was trans-2 decenoic acid,
which shares similar structure to farnesol and X. campestris DSF, thus was given the
name Streptococcus diffusible factor (SDSF) (see Table 1.2) (Vílchez et al. 2010).
SDSF from stationary cultures inhibits C. albicans hyphal formation, but, this effect is
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only observed at 2 and 4 hours of incubation and dissipates after 6 hours (Vilchez et al.
2010). SDSF was also able to reduce the expression of hyphal specific genes HWP1
and SAP5 (Vílchez et al. 2010). Researchers found that SDSF production was not
limited to S. mutans but also found in S. sanguinis, S. oralis, and S. mitis (Vílchez et al.
2010). Another molecule produced by S. mutans, mutanobactin A, has been shown to
inhibit the yeast to hyphal morphological shift (Joyner et al. 2010). S. mutans can inhibit
germ tube formation even when physically separated from C. albicans. Spent media
from 4 hours inhibits germ tube formation, but 6, 8, and 24 hour does not (Jarosz et al.
2009). Competence stimulating peptide (CSP), a 22 amino acid peptide, acts as a QSM
of S. mutans and is produced in the beginning of exponential growth phase (Jarosz et al
2009). Mutants of comC that encodes CSP could not reproduce this inhibition (Jarosz
et al. 2009). CSP does not inhibit growth nor evoke stress response or significantly
inhibit biofilm formation (Jarosz et al. 2009). Other Streptococcus species tested had
varying effects similar to S. mutans (Jarosz et al. 2009).
Indole is a molecule shared among both Gram-positive and Gram-negative
bacteria that is hypothesized to be a QSM of E. coli used in the communication of
biofilm populations (Lee and Lee 2010). Raut et al. observed that physiologically
relevant levels of indole inhibited C. albicans growth, germ tube formation, adhesion,
and blocked biofilm formation (Raut et al. 2012). Oh et al. (2012) found that indole was
able to reduce the attachment of C. albicans to human epithelial cells at concentrations
that did not affect the viability of human cells. Additionally, in a C. elegans model,
indole was able to inhibit filamentation, increase survival of the worm, and led to an
overall lower C. albicans burden (Oh et al. 2012). When examining the effects of indole
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on C. albicans gene expression it was unexpectedly found that genes that are normally
affected by bacterial influences on C. albicans virulence, most notably ALS3 and HWP1,
were unaffected; however, NRG1, a transcriptional repressor of filamentation, was
greatly increased (Oh et al. 2012).
Peptidoglycan (PPG) constitutes the cell wall of both Gram-positive (in large
amounts) and Gram-negative bacteria (in smaller amounts). Xu et al. (2008) found that
PPG from E. coli and S. aureus did not alter C. albicans morphogenesis, but when PPG
is hydrolyzed it can promote hyphal morphology. The subunit of PPG that was shown
to be the active inducer of hyphae was muramyl dipeptide (Xu et al. 2008). Purified and
synthetic muramyl dipeptides interact with Cyr1p and Ras1p for the signaling of hyphal
development (Xu et al. 2008). Serum, depending on the source, is a potent inducer of
hyphae and PPG can be readily found in serum (Xu et al. 2008). PPG is also found in
the intestines where C. albicans may use it to induce filamentation for invasion (Xu et al.
2008).
Lipopolysaccharides (LPS), large lipid polysaccharides, are major constituents of
Gram-negative bacterial membranes. As mentioned previously, E. coli LPS has no
effect on C. albicans biofilms but has varying effects on other Candida species
(Bandara et al. 2009). Bandara et al. (2010) also examined different bacterial LPS
effects on biofilm growth using a number of different Candida species, again finding that
the effect is Candida species specific. Serratia marcescens, and Salmonella
typhimurium LPS had no significant changes in C. albicans biofilms at any stage
(Bandara et al. 2010). P. aeruginosa LPS significantly increased C. albicans metabolic
activity during biofilm attachment (0-90 minutes) phase, with increases in yeast cell
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numbers as well as the presence of numerous dead C. albicans cells (Bandara et al.
2010). Klebsiella pneumonia LPS also produced significant increases in metabolic
activity at both the attachment and maturation (90 min-24 hours) of C. albicans biofilms
(Bandara et al. 2010). The overall message was that LPS from different bacterial
species affect different Candida species in different ways in a time, concentration, and
species dependent manner (Bandara et al. 2010). Generally, higher concentrations of
LPS from both bacteria inhibited C. albicans metabolic activity, while lower
concentrations enhanced metabolic activity (Bandara et al. 2013). P. aeruginosa LPS
resulted in increased yeast cell morphology and decreased hyphal cell morphology in
biofilms with “patchy” architecture, but the cells were still viable (Bandara et al. 2013).
LPS from both P. aeruginosa and K. pneumonia increased expression of hyphal specific
genes and P. aeruginosa LPS inhibited protein synthesis in C. albicans (Bandara et al.
2013). One factor that could explain the varying effects of LPS on C. albicans could be
the small differences in LPS structure between strains as well as differences between
species.
Lactobacillus rhamnosus bacteria inhibit C. albicans germ tube formation, while
heat killed bacteria are unable to (Nover and Huffnagle 2004). Bacterial supernatant
from 2 hour (30-55%) and 24 hour (92-98%) growth of L. casei, L. paracasei, and L.
rhamnosus all inhibited germ tube formation (Noverr and Huffnagle 2004). Noverr et al.
tested a number of short chain fatty acids readily produced by Lactobacillus and butyric
acid, inhibited in a concentration dependent manner (Noverr and Huffnagle 2004).
When gene expression is examined in C. albicans-Lactobacillus coculture there are
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changes drug exporters, stress responses, transport, signal transduction, and targets of
fluconazole gene expression (Köhler et al. 2012).
Streptococcus gordonii stationary phase media can induce hyphal formation in C.
albicans, but a S. gordonii luxS mutant, with a deletion for AI2 QS, cannot produce the
induction of hyphae (Bamford et al. 2009). Precursors of AI2 used to mimic AI2 could
not rescue the lux2 mutant’s ability to induce hyphae in C. albicans (Bamford et al.
2009). Thus, either the precursors of AI2 used in this experiment are a poor substitute
or there are other secreted factors causing hyphal induction (Bamford et al. 2009).
Salmonella typhimurium media from stationary growth inhibits C. albicans
filamentation, whereas media from exponential growth does not (Tampakakis et al.
2009). There is no known QSM associated with S. typhimurium; however, it does have
a QS sensor sdiA that can respond to other bacterial QSMs (Tampakakis et al. 2009).
Supernatant form S. typhimurium stationary growth suppresses C. albicans TEC1,
HWP1, ALS3, and CDC42 gene expression (Tampakakis et al. 2009).
Table 1.2 Bacterial molecules associated with Candida-bacterial interactions.
Effect on
Microorganism
Proposed Molecule(s)
Reference
C. albicans
Acinetobacter
(Peleg et al. 2008)
Unknown
Inhibitory
baumannii
Burkholderia
Dodecenoic acid
(Zhang et al. 2011)
Inhibitory
cenocepacia
Escherichia
(Nair et al. 2001)
Unknown
Inhibitory
coli
Lactobacillus
(Noverr and Huffnagle 2004)
Butyric acid
Inhibitory
rhamnosus
Pseudomonas
HSL, HHQ, Decenoic acid,
(Kerr et al. 1999; Hogan et al.
Inhibitory
2004; Davies and Marques 2009)
aeruginosa
Pyocyanin, Phenazine
Salmonella
(Tampakakis et al. 2009)
Unknown
Inhibitory
typhimurium
Staphylococcus
Inhibitory
Unknown
aureus
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Table 1.2 (continued)
Streptococcus
gordonii
Streptococcus
mutans
Xanthamonas
campestris
Various bacteria
Various bacteria
Various bacteria

AI-2

Enhancing

(Bamford et al. 2009)

Decenoic acid, CSP
Mutanobactin A

Inhibitory

(Jarosz et al. 2009; Joyner et al.
2010; Vílchez et al. 2010)

Dodecenoic acid

Inhibitory

(Wang et al. 2003)

Indole
LPS
PPG subunits

Inhibitory
Varying
Enhancing

(Raut et al. 2012)
(H.M.H.N. Bandara et al. 2010)
(Xu et al. 2008)

Farnesol’s Effect on Bacteria
Farnesol has numerous observed effects on several bacteria (see Table 1.3).
For instance, swarming motility of P. aeruginosa is inhibited by farnesol (McAlester et al.
2008). Additionally, farnesol inhibits the production of PQS in P. aeruginosa, which
directly inhibits pyocyanin production (Cugini et al. 2007). This action can be
suppressed by higher levels of PQS (Cugini et al. 2007). Cugini et al. (2010) also found
that P. aeruginosa strains defective in the LasR QS system and PQS production can be
restored by the addition of farnesol resulting in increased pyocyanin and phenazine
production.
Farnesol is able to compromise S. aureus and S. epidermidis membrane integrity
and sensitize them to antimicrobials (see Table 1.3) (Meiller et al. 2006; Pammi et al.
2012). In S. aureus biofilms extremely high concentrations of farnesol (30mM) are able
to inhibit formation, reduce the number of viable bacteria, and prevent further growth of
preformed biofilms (Unnanuntana et al. 2009).
When C. albicans establishes a quorum, after 8 hours of biofilm growth, it is able
to inhibit A. baumannii growth (Peleg et al. 2008). Synthetic farnesol added to media
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also inhibited A. baumanii growth and mutants defective in farnesol production are
unable to inhibit A. baumannii (Peleg et al. 2008).
Finally, S. mutans membrane permeability is hindered in the presence of farnesol
(Jeon et al. 2011). Additionally, when applied to mixed species biofilms of commonly
found oral bacteria, farnesol inhibits the competitiveness of S. mutans and reduces its
dominance over other species in the polymicrobial biofilms (Jeon et al. 2011).
In polymicrobial communities of bacteria and Candida there is a microbial chess
match to gain a competitive advantage for limited resources and space. Often, with
every movement by one microorganism, especially when involving chemical molecules,
there is a counter move made by the competing microorganism. Farnesol appears to
serve as both a regulator of C. albicans morphogenesis as well as a chemical counter
attack to bacterial competitors.
Table 1.3 Reported effects of Candida albicans farnesol on bacteria.
Bacteria
Effect of Farnesol on Bacteria
Reference
Acinetobacter
(Peleg et al. 2008)
Inhibits growth
baumannii
Escherichia
Increases antibiotic sensitivity
(Brehm-stecher and Johnson
2003)
coli
Pseudomonas
Inhibits PQS, pyocyanin, swarming
(Cugini et al. 2007; McAlester et
al. 2008; Cugini et al. 2010)
aeruginosa
motility
Staphylococcus
Compromises cell membrane integrity,
(Meillereet al. 2006)
aureus
Increases antibiotic sensitivity
Staphylococcus
Compromises cell membrane integrity,
(Pammi et al. 2012)
epidermidis
Increases antibiotic effectivity
Streptococcus
Compromises membrane integrity,
(Jeon et al. 2011)
mutans
Prevents biofilm dominance

45

Specific Aims
Recent research has shown that C. albicans can respond to bacterial QS
molecules (Hogan and Kolter 2002; Boon et al. 2008; Peleg et al. 2008). In addition to
QSMs, bacteria secrete metabolites, antibiotics, and other molecules into their
environment that could also be types of communication. This would imply that there are
signaling or genetic pathways that C. albicans uses to detect bacterial QSMs, as well as
other metabolites, that regulate C. albicans ability to filament. Thus, we hypothesize
that C. albicans uses more than one pathway to regulate filamentation in the presence
of bacteria. In many instances bacteria can inhibit the ability of C. albicans to change its
morphology, thus inhibiting the yeast to hyphal shift (Hogan and Kolter 2002;
Tampakakis et al. 2009). The understanding of this process and the pathways involved
has, thus far, not been defined. Only a single gene CHK1 has been shown to be
genetically linked to C. albicans QS, which cannot account for all modes Candidabacterial interactions (Kruppa et al. 2004). To better characterize this process, the
implementation of a genetic screen to aid in the identification of genes that are involved
in the regulation of C. albicans ability to filament in the presence of Gram-positive and
Gram-negative bacteria could prove very useful. This would allow for identification of
common as well as bacteria-specific linked genes/pathways that modulate filamentation
of C. albicans.
AIM 1: Screen a C. albicans transposon insertion library to identify candidates that
filament in the presence of bacteria and identify the insertion site of the transposon
within the C. albicans genome (Chapter 2).
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AIM 2: Characterize the involvement of C. albicans CDR4 in the regulation of
filamentation in the presence of bacteria (Chapter 3).
AIM 3: Characterize the involvement of C. albicans ALS6 in the regulation of
filamentation in the presence of bacteria (Chapter 3).
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Abstract
In the human body, fungi and bacteria share many niches where the close contact of
these organisms maintains a balance among the microbial population. However, when
this microbial balance is disrupted, as with antibiotic treatment, other bacteria or fungi
can grow uninhibited. C. albicans is the most common opportunistic fungal pathogen
affecting humans and can uniquely control its morphogenesis between yeast,
pseudohyphal, and hyphal forms. Numerous studies have shown that C. albicans
interactions with bacteria can impact its ability to undergo morphogenesis; however, the
genetics that govern this morphological control via these bacterial interactions are still
relatively unknown. To aid in the understanding of the cross-kingdom interactions of C.
albicans with bacteria and the impact on morphology we utilized a haploinsufficiency
based C. albicans mutant screen to test for the ability of C. albicans to produce hyphae
in the presence of three bacterial species (Escherichia coli, Pseudomonas aeruginosa,
and Staphylococcus aureus). Of the 18,144 mutant strains tested, 295 mutants
produced hyphae in the presence of all three bacterial species. The 295 mutants
identified 132 points of insertion, which included identified/predicted genes, major
repeat sequences, and a number of non-coding/unannotated transcripts. One gene,
CDR4, displayed increased expression when co-cultured with S. aureus, but not E. coli
or P. aeruginosa. Our data demonstrates the ability to use a large scale library screen
to identify genes involved in Candida-bacterial interactions and provides the foundation
for comprehending the genetic pathways relating to bacterial control of C. albicans
morphogenesis.
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Introduction

Polymicrobial communities of bacteria and fungi play a pivotal role in both human health
and disease and can be found on nearly all facets of the human body including the
skin, mouth, lungs, gastrointestinal, urinary, and reproductive tracts [1]. As varied as
the habitats these microbes reside in are the types of interactions (both chemical and
physical) that the opportunistic fungal pathogen Candida albicans and bacteria have
with one another, which are only recently being fully appreciated by the scientific
community [1,2]. C. albicans ability to change morphology from a budding yeast to a
filamentous hyphae is considered a major virulence factor [3,4] that is influenced
through a variety of environmental and host factors, including temperature, serum, pH,
nutrient availability, and quorum sensing (QS) [5]. QS in C. albicans is regulated by the
molecule farnesol [6], which when present at saturating levels, inhibits the ability of C.
albicans to shift from yeast to hyphal form. This type of chemical communication
among a population has also been well documented in bacteria [7–10]. Recent
research has shown that bacterially secreted quorum sensing molecules (QSMs) and
other metabolites can influence C. albicans morphology as well. For example,
Pseudomonas aeruginosa secretes the QS molecule (QSM) 3-oxo-C12 homoserine
lactone (3OC12HSL) that can block C. albicans filamentation [11]. Likewise,
Burkholderia cenocepacia’s diffusible signal molecule, cis-2 dodecenoic acid, has been
shown to inhibit C. albicans germ tube formation [12]. Similar inhibitory effects can be
observed when C. albicans interacts with the bacteria Acinetobacter baumannii and
Streptococcus mutans or the yeast Saccharomyces boulardii [13–15]. Interestingly,
different bacterial species from the same genus, as in the case of Streptococcus, can
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have opposing effects on C. albicans morphology. For instance, the oral bacterium S.
mutans inhibits hyphal formation of C. albicans via the QSMs trans-2-decenoic acid and
competence stimulating peptides [14,16]; however, S. gordonii appears to stimulate C.
albicans hyphae formation in an effort to aid in the colonization of the oral cavity [17].
These results suggest that C. albicans has mechanisms in place that can recognize
these bacterial molecules in the environment and respond accordingly.
Physical interactions between bacteria and C. albicans include both attachment
and the development of mixed species biofilms on both biotic and abiotic surfaces [18].
In addition to P. aeruginosa secretion of 3OC12HSL, the bacterium preferentially
attaches to and kills the C. albicans hyphal form, but not the yeast form [19].
Alternatively, Staphylococcus epidermidis enjoys the ability of attaching to both the
yeast and hyphal forms of C. albicans, and when found together as in a mixed biofilm,
enhances C. albicans resistance to fluconazole [20]. Additionally, S. aureus
preferentially attaches to C. albicans hyphae and these mixed biofilms show increased
drug resistance to Vancomycin [21–23]. On the other hand, farnesol has been shown to
disrupt S. aureus membrane integrity making it more susceptible to antibiotics as well
as interfering with biofilm growth [24]. From a virulence standpoint, co-infection of C.
albicans and other bacterial species, including S. aureus, E. coli and P. aeruginosa,
show synergy with increased mouse mortality when the organisms are infected at
sublethal doses [23,25–28]. Furthermore, prior colonization of E. coli in the urinary
tract enhances C. albicans ability to colonize and subsequently cause urinary tract
infections where typically it is unable to do so [29]. These trans-kingdom interactions
may indicate that microorganisms utilize the nearby molecules to sense and monitor
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their shared surrounding, adapt to changes in the local environment, and survive within
a mixed species population. Despite the recent influx of research into Candida-bacterial
interactions little is known about the genetics behind the mechanisms of communication
that govern these interactions, and how they control morphological change in C.
albicans.
Multiple species of bacteria are known to inhibit C. albicans filamentation and our
goal was to identify mutants that did not respond when cultured in the presence of
bacteria. In the present study, we utilized a large scale haploinsufficiency based screen
to identify the genetic elements regulating C. albicans filamentation in the presence of
bacteria. To our knowledge, this screen is the first to identify genetic determinants
involved in polymicrobial interactions of C. albicans with bacteria and how they control
morphogenesis of C. albicans. We identified 132 different genetic elements that appear
to be involved in the ability of C. albicans to filament in the presence of three different
bacteria (E. coli, P. aeruginosa, S. aureus). The results from this screen begin to offer a
better understanding of the genetics behind Candida-bacterial interactions as well as
factors influencing the morphogenesis of C. albicans.
Materials and Methods
Strains, media, and growth condition. C. albicans wild type SC5314 [30], was
routinely cultured on Yeast Peptone Dextrose (YPD) medium (2% dextrose, 2%
peptone, 1% yeast extract, 2% bacto agar) at 30°C. The CDR4 deletion strains
[SFLUC6 (cdr4/CDR4) and SFLUC4 (cdr4/cdr4] have been previously described by
Morschhäuser et al. [31]. The ALS6 deletion strains [1522 (als6/ALS6) and 1420
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(als6/als6)] have been previously described by Hoyer et al. [32]. E. coli
(ATCC#33922), P. aeruginosa (ATCC#27853), and S. aureus (ATCC#25923) strains
were maintained on Luria Broth (LB) medium (1% tryptone, 1% NaCl, 5% yeast extract,
2% bacto agar) at 37°C.
Screen for filamentation mutants. A transposon insertion library of 18,144 C.
albicans strains was constructed using C. albicans strain CAI4 [33] and a Tn7 plasmid
insertion library created by Uhl et al [34]. To perform the screen for filamentation, the
library strains were individually spot replicated, with two centimeter spacing, onto YPD,
Medium 199 (M199) (9.5g medium 199 with Earles salts, 18.7g Tris-HCl, 20g bacto
agar, pH 7.5), or M199 plates that had been pre-coated with bacterial lawns from fresh
37°C overnight cultures. The YPD plate was incubated at 30°C for 48 hours and served
as a positive control for growth and a negative control for filamentation. The M199
control and bacterial plates were incubated at 37°C and were monitored for
filamentation for up to seven days. The M199 control plate (without bacteria) served as
a positive control for filamentation. Library candidates that filamented in the presence of
bacteria were compared to the wild type control (SC5314) and retested twice under the
same conditions to confirm the filamentous phenotype.
Filamentation in liquid media. C. albicans strains were grown overnight at 30°C,
washed three times with dH2O and cells counted with a hemocytometer. 1x106 cells/mL
were inoculated into pre-warmed medium 199 pH7.5 (37°C, control) or medium 199
pH7.5 containing bacteria that were pre-grown overnight at 37°C. This provided a high
concentration of bacteria to simulate crowding conditions for C. albicans. For spent
media the bacteria were spun out by centrifugation 5 min at 8,000 x g, then the medium
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was filtered to ensure removal of any remaining bacterial cells. The spent media was
then inoculated with the C. albicans strains. The Candida strains were incubated for 2.5
hr at 37°C and morphology was assessed microscopically.
Mapping of transposon insertion sites. C. albicans library candidates that filamented
in the presence of all three bacteria were inoculated into 5mL of YPD and incubated
overnight at 30°C with shaking (155rpm). Cells were harvested by centrifugation and
chromosomal DNA was obtained using a standard bead extraction [35]. Chromosomal
DNA was digested with BsrgI (New England), diluted 1:100, and treated with T4 DNA
ligase (New England) to allow for the reconstitution of the original insertion plasmid.
The ligated DNA was then transformed into E. coli TB-1 cells that were made competent
with calcium chloride [36]. The transformed cells were plated onto LB agar plates with
50 µg/mL ampicillin and incubated overnight at 37°C. The successfully transformed
cells were then grown overnight in 5 mL of LB with 50 μg/mL ampicillin and plasmid
DNA was purified using the Promega Wizard© Plus DNA purification system. Purified
plasmids were sequenced using primers MKOL544: 5’GATCTGAGTGAGCATCAACAG-3’ or MKOL525 5’GCTATGACCATGATTACGCCAGG-3’ that recognize the 5’ and 3’ flanking sequences
of the transposon allowing for sequencing on either side of the insertion point. The
resulting DNA sequences were used to search the Candida Genome Database by
BLAST comparison to identify the region of transposon insertion [37].
Reverse transcription and gene expression. C. albicans SC5314, E. coli, P.
aeruginosa, and S. aureus strains were grown in 50 mLs of YPD at either 30°C or 37°C
until they reached mid-log phase. Cells were then harvested by centrifugation, washed
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with 1X PBS, and resuspended in 50 mLs of M199. C. albicans SC5314 and single
species bacteria were then combined in equal amounts and incubated (at 30°C or 37°C)
with shaking (155rpms). Aliquots were taken at 0, 10, 20, 30, 60 minutes post addition,
cells were harvested, and samples were frozen. Acid phenol RNA extraction was
performed on the samples to extract total RNA [35]. Reverse transcription PCR was
performed using a Verso 1-Step RT-PCR kit (Thermo-Fisher). Primers MKOL597 5’GGCAGATGCC GATACGAGTTCAAATTCG-3’ and MKOL598 5’CATCAGAAGCCGAACC ATAAGCACGC-3’ were used for CDR4 RNA detection. The
ENO1 gene served as a loading control using primers MKOL188 5’ –
CGACTCCAGAGGTAACCC- 3’ and MKOL189 5’ – CCCAAGCATCCCAGTC – 3’.
Primers for ALS6 detection were used as described by Zhao et al [38]. Images were
captured using a Syngene G:Box system and analysis was performed using Gene Tools
software by SynGene. The experiments were performed three times; the data were
quantified and statistically analyzed by a student’s t-test. P-values were calculated and
those that were significant (P<0.05) were noted.
Results
Identification of 295 C. albicans mutant strains that filament in the presence of
three bacterial species. To identify the genetic elements involved in C. albicans
polymicrobial interactions, we utilized a C. albicans transposon insertion mutant library
previously described by Uhl et al [34]. The library was spot replicated, along with a wildtype (SC5314) control onto agar plates of YPD, M199, and M199 containing a lawn of
either E. coli, P. aeruginosa or S. aureus. To control for hyperfilamentous mutants and
remove them from the screen, strains were grown on YPD at 30°C while mutants that
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did not filament were screened out on M199 at 37°C. We chose the test conditions of
growing the strains on freshly spread bacterial lawns as this would result in a
competitive growth condition for the Candida strains in the presence of bacteria. Our
choice of the Gram positive, S. aureus, and the two Gram negative, E. coil and P.
aeruginosa, was due to their association with host environments that C. albicans is
often known to colonize. We scored the strains to determine if the C. albicans mutants
filamented in the presence of one, two or all three bacterial species. Overall we
identified 836 strains (4.60% of the entire mutant population) that filamented in the
presence of one or more of the bacteria. The systematic screening of the transposon
insertion library identified 295 individual strains that produced a filamentous phenotype
in the presence of all three bacterial species. We also identified 271 strains that
filamented in the presence of two of the three bacterial species and 270 that only
filamented in the presence of one species of bacteria. We decided to focus our efforts
on the mutants that filamented in the presence of all three bacterial species as these
mutants would likely be linked to a common mechanism for C.albicans to respond to
different species of bacteria. Figure 2.1 depicts representative phenotypes of both the
wild-type control as well as a C. albicans transposon library strains that produced
filaments in the presence of bacteria. On YPD at 30°C, the SC5314 control shows a
colony’s typical yeast, non-filamentous, morphology with characteristic smooth rounded
edges (Figure 2.1 A, D) while its growth on M199 without bacteria at 37°C shows
hyphal filaments protruding from the colony (Figure 2.1 B, E). SC5314 grown in the
presence of high concentrations of bacteria lack filaments around the colony (Figure
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2.1 C, F) while the mutants identified by our screen exhibit filamentation in the presence
of all three bacterial species (Figure 2.1 G-I).

Figure 2.1 Representative colony morphologies. (A) SC5314 wild-type nonfilamentous growth on YPD agar (30°C); (B) SC5314 wild-type filamentation on M199
agar (37°C); (C) SC5314 wild-type filamentation inhibition in the presence of P.
aeruginosa on M199 agar (37°C); (D) 4X magnification of A; (E) 4X magnification of B;
(F) 4X magnification of C; (G), (H), (I) Representative examples of library mutant
filamentation in the presence of bacteria due to haploinsufficiency on M199 agar (37°C)
(4X magnification)
Localization of the Tn7 transposon insertions. To identify the region of genome that
the transposon insertion was located, the recovered insertion plasmid constructs were
sequenced and the resulting sequences were then mapped by BLAST search of the
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Candida Genome Database (CGD) [37]. The 295 library candidates were mapped to
132 points of insertion within genes and other genetic components of the Candida
genome, multiple independent candidates were shown to map to the same gene further
validating the genetic screen. Fifty percent of the Tn7 insertions mapped within an open
reading frame (ORF) while 18% of the insertions mapped to the 5’ upstream region and
13% to the 3’ downstream of an ORF (Supplementary Table 2.1). This accounted for
107 known/predicted genes that fell into an array of categories related to gene function
including enzymatic activity, transport, transcription, signaling, and adhesion (Table
2.1). By far, the majority of identified genes and ORFs fell into the category of unknown
function. From our screen we noted that the majority of the candidates we identified
had not been previously associated with filamentation in general. However the SSU1,
FGR10, FGR24, RAS2, MRP2, and CCR4 haploinsufficient mutants we identified in our
screen also overlap with the dataset from a haploinsufficient library screen performed by
Uhl et al. [34] for filamentous mutants. In their study, Uhl et al [34] screened for
hyperfilamentous and less filamentous mutants using different conditions than we
utilized in this study. These mutants did not show any hyperfilamentous or less
filamentous phenotypes under our control conditions indicating variability between the
two experimental approaches.
A number of insertions (5%) were mapped to the RPS and RB2 repeat regions
located within the major repeat sequences (MRS) of MRS-1, -2,-4,-6, -7a, -7b, and –R
units (Supplementary Table 2.2). There were no Tn7 insertions found within MRS-5,
nor the partial RB-2-4a repeat unit. Within the RB2 repeat region, Uhl et al previously
identified a family of genes, FGR6, which have no clearly defined function other than
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their association with fungal growth [34]. It appears that at least seven of eight FGR6
family members (FGR6-1, FGR6-3, FGR6-4, FGR6-10, orf19.727, orf19.6896,
orf19.5775) are involved in regulating filamentous growth in the presence of bacteria.
Finally, 14% of the insertions were mapped to non-coding transcripts or unannotated
ORFs (Supplementary Table 2.3). Many of these transcripts were characterized
previously by RNA-seq analysis [39] and tiling arrays [40], but have not been further
characterized regarding their functional roles in the cell. We use the term “transcripts”
at this time as the transcribed regions have not been designated officially as protein
coding ORFs or regulatory RNA genes in the CGD.
Table 2.1. Biological process categories of genes identified from library screen
Biological Process

Gene/orf identified

Enzymatic activity

ALK8, FMO1, GCA2, GOR1, GCV1, IAH1, PLC1, orf19.346, orf19.511, orf19.1110,
orf19.2114, orf19.4112, orf19.4246, orf19.5169, orf19.5665, orf19.7152
orf19.7512

Adhesion

ALS6, EAP1, PGA28, orf19.5813

Cell wall associated

BMT8, GSC1, GSL1, PGA52

Cell cycle

IRR1, MAD2, NUF2, TEM1

Signal transduction

CAS4, RAS2, TOR1

Transport

CDR4, CRM1, GNP3, MGE1, POM152, RTA3, SSU1, orf19.6592, orf19.6747

Transcription

BDF1, CCR4, CTA24, CRZ2, HAP31, PHO23, SPT7, SUA72, ZCF11, orf19.536
orf19.470

Translation

MRP2, TIF5, orf19.4176

Protein processing

DNM1, orf19.3730, orf19.3767, orf19.4086, orf19.5212, orf19.6082,
orf19.7358

Proteolysis

AXL1, FGR10, orf19.4610

RNA processing

ILS1, NHP2, POP3, SEN1, orf19.1201, orf19.6736, orf19.6931

RNA binding

orf19.3124, orf19.4018

DNA binding

orf19.2579, orf19.7301

DNA repair

MEC3, SMC5, orf19.4412, orf19.6722, MMS21
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Ribosomal
associated
Amino acid
synthesis
Autophagy
Unknown

SOF1,RPS12, RPS18
CHA1, ECM17, HPA2
SPO72, orf19.2982
FGR34,orf19.344, orf19.1368, orf19.1728, orf19.2038, orf19.2106,
orf19.3087.2,
orf19.3100, orf19.3394, orf19.3643, orf19.4263, orf19.5799, orf19.5897
orf19.6488, orf19.6968, orf19.7085, orf19.7130, orf19.7567

Confirmation of phenotypes for cdr4/CDR4 and als6/ALS6 haploinsufficient
mutants. Although we identified independent insertions near or within the same gene
multiple times from this screen, to further confirm our observed phenotypes we chose
two mutants, als6/ALS6 and cdr4/CDR4, to be tested using independently
constructed heterozygous and homozygous null strains. The ALS6 mutant was chosen
as the original Tn7 library insertion point was in the promoter region of this gene, while
the CDR4 mutant was chosen as the insertion fell within the open reading frame. The
als6 and cdr4 heterozygous and homozygous null strains (obtained from Drs. Hoyer and
Morschhäuser) were spot replicated with our haploinsufficient als6/ALS6 and

cdr4/CDR4 library strains onto YPD, M199, and M199/bacterial plates using the same
conditions from the original library screen. The phenotypes of the als6 and cdr4
heterozygous and homozygous null strains were similar if not identical to those we saw
with our Tn7 mutant isolates (Figure 2.2), thereby confirming our original observations
and the validity of using haploinsufficiency for characterizing bacterial-Candida
interactions. Furthermore, we examined the morphology of the strains in liquid culture
in the presence of bacteria and spent media (Supplementary Figure 2.1). When cells
were cultivated under hyphal inducing conditions in M199 we observed all strains
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exhibiting a hyphal morphology, whereas the control strain showed clear impairment of
filamentation when grown in the presence of all three bacterial species. All the mutant
strains filamented in the presence of all three bacterial species with hyphae being the
predominant morphology (Supplementray Figure 2.1A). Also when C. albicans was
inoculated into spent media that the bacteria had been removed from the mutants were
capable of filamenting as hyphae and the wild type strain was impaired as mainly yeast
and some pseudohyphae (Supplementary Figure 2.1B). This result also suggests that
primary mediator(s) inhibiting C. albicans filamentation are secreted actively by the
bacteria.

Figure 2.2 Representative photos of observed phenotypes of SC5314, library
transposon candidates, and cdr4 and als6 heterozygous and homozygous
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deletion strains. YPD growth control (30°C), 40x magnification; M199 filamentation
control (37°C), 100x magnification; E. coli interactions with C.albicans strains, 100x
magnification; P. aeruginosa interactions with C. albicans strains, 100x magnification; S.
aureus interactions with C. albicans strains, 100x magnification.

C. albicans CDR4 expression increases in the presence of S. aureus. C. albicans
and the individual bacterial strains were co-cultured and CDR4 transcript levels were
analyzed over time. The SC5314 cells co-incubated with S. aureus at 37°C exhibited
over a two-fold increase in CDR4 expression over the time course of 60 minutes as
compared to the SC5314 control without bacteria (Figure 2.3 and Supplementary
Figure 2.2). There was little to no change in CDR4 expression in the presence of E.
coli or P. aeruginosa, nor was there any change in CDR4 expression when tested at
30°C with any of the three bacterial species (data not shown). We also observed that
spent bacterial culture media (bacteria removed by filtration) was unable to stimulate the
expression of CDR4 (data not shown). This suggests that a combination of physiologic
temperature and (in the case of S. aureus) some sort of contact between the organisms
is required for CDR4 induction. Others have shown that changes in morphology and
growth may require live bacteria to be present in the media to have a full inhibitory effect
on Candida filamentation [13]. This would suggest that C. albicans interactions with
bacteria are multifactorial encompassing both contact dependent mechanisms as well
as secreted molecular factors. We also examined the expression of ALS6, however no
increase in transcript level was observed with any of the growth conditions (data not
shown).
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Figure 2.3 C. albicans CDR4 transcript levels grown in the presence of bacteria.
C. albicans SC5314, E. coli, P. aeruginosa, and S. aureus were grown to mid log phase
in liquid culture, mixed together in equal amounts, co-incubated at 37°C, and aliquots
were taken at 0, 10, 20, 30, and 60 minutes post addition. RNA was isolated and
expression of CDR4 was measured by reverse transcription. ENO1 was used as a
loading control and reference gene for expression comparisons. Graphical
representation of CDR4 expression over time for SC5314 co-incubated with E. coli, P.
aeruginosa, or S. aureus. Data is representative of three independent experiments with
mean value and standard deviation bars shown. The asterisks indicate a statistically
significant difference (P<0.05) in mean intensity of test conditions over the control.

Discussion
The microbiome of the human body plays an important role in our health. Currently,
studies involving the microbiota have only examined what the microbial population
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structures appear to be in both healthy and diseased individuals [41–43]. Because the
opportunistic fungus C. albicans is a member of normal flora, it is thought that C.
albicans growth is held in control by other microorganisms as well as the hosts’ immune
system. Patients that are immunocompromised or those being treated with broad
spectrum antibiotics can create an environment allowing C. albicans the opportunity to
expand its growth due to the reduction of factors secreted by other organisms that
would normally suppress filamentous growth. In order to understand how both Gram
positive and Gram negative bacteria impair C. albicans ability to filament we performed
a genetic screen using haploinsufficiency to identify common targets in C. albicans that
are used by both types of bacteria to impair C. albicans growth. Though it is an
imperfect means to screen for all possible genes related to a particular phenotype due
to the diploid nature of C. albicans, haploinsufficiency has been used previously to
identify strains showing reduced or increased filamentation [34] as well as changes in
fitness related to drug susceptibility and growth rates [44]. Using this approach we were
successful in identifying 107 genes/ORFs that likely play some role in C. albicans
filamentation response in the presence of various bacterial species.
The genes identified from this screen fell into a variety of biological functions
including adhesion, cell cycle, enzymatic activity, signaling, transcription, and transport.
For example, the identification of several genes involved in various types of transport
was quite surprising. Several of the genes we identified were associated with the
plasma membrane (CDR4, RTA3, and GNP3) while others were associated with
nuclear (CRM1, POM152) or mitochondrial (MGE1, SSU1, orf19.7358) transport. The
transporters associated with the plasma membrane likely are used by C. albicans for
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import/export of bacterial metabolites and QS molecules from the surrounding
environment. We speculate that mutations in the CRM1 or POM152 genes may be
interfering with export/import of signaling proteins or transcriptional regulators required
to respond to the presence of bacteria in the environment. It is quite possible that
MGE1, SSU1, or orf19.7358 transporters may be involved in transporting bacterial
molecules that interfere with several other genes associated with mitochondrial function
(DNM1, GCU1, MRP2, orf19.346, orf19.1201, orf19.4176, orf194018, orf19.4472, and
orf19.7152), as mutants of these genes were also shown to be impaired in the
filamentation response to all three bacteria. The cdr4, rta3 and gnp3 mutants are
interesting in that Rta3p is a predicted flippase, which may participate in lipid molecule
translocation across the membrane. Likewise the Gnp3p is predicted to be a high
affinity glutamine transporter which could serve as a point for small peptide transport.
Additionally, Cdr4p has no characterized functional role even though it is a member of a
family of ABC transporters, Cdr1-3p [45,46]. Cdr1p and Cdr2p are important in C.
albicans drug resistance [46,47], while Cdr3p is involved in import of phospholipids [45].
It is possible that Cdr4p plays a role in the import of small peptides or other molecules
as ABC transporters have been implicated in peptide transport in S. aureus as well as
autoinducer-2 transport in E. coli [48,49]. We did observe that heterozygous and
homozygous mutants of CDR4 display identical phenotypes to that of our original library
isolate, further implicating its role in C. albicans interaction with bacteria. Surprisingly,
CDR4 expression was only induced when S. aureus was present in the environment
with C. albicans. S. aureus, along with several other Gram positive bacteria, is known
to produce small peptide QS molecules. It may be that close contact with C. albicans
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results in the liberation of these molecules from S. aureus and C. albicans increases its
expression of CDR4 in response to these peptides. This may also be specific to Gram
positive bacteria, for example, when C. albicans is co-cultured with Lactobacillus
rhamnosus or Lactobacillus reuteri there is a two to three fold increase in CDR4
expression [50], Since we did not observe any major change in CDR4 expression when
C. albicans was grown with E. coli or P. aeruginosa, may indicate that these organisms
don’t produce a peptide required for CDR4 induction. The fact that mutants lacking
CDR4 or have reduced expression of the protein may indicate that Cdr4p is playing a
role as an importer of bacterial peptides and other molecules as well as C. albicans
inability to block filamentation in response to the presence of bacteria is a direct result of
Cdr4p’s absence.
A second categorical group identified from the screen is the four genes (ALS6,
EAP1, PGA28, and orf19.5813) that are associated with adhesion. Previous work had
found that the attachment of C. albicans to S. gordonii involves multiple interactions
between several components of the bacterial cell wall and C. albicans components [51].
Recently, it had been shown the EAP1 and ALS3 genes, when expressed in S.
cerevisiae, conferred the ability of S. gordonii to attach to S. cerevisiae [52]. The ALS3
gene has also been shown to be involved in mediating aggregation and, more
specifically, directing the attachment of S. aureus to the hyphal form of C. albicans [53].
The identification of the eap1 mutant in our screen may indicate that the protein plays
not only a role in adherence to bacterial surfaces but may somehow be linked to C.
albicans ability to “sense” other organisms in its environment. ALS6 belongs to the ALS
family of adhesins involved in attachment to biotic and abiotic surfaces, biofilm
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formation, and virulence, however the specific role of ALS6 is unknown at this time [52–
54]. Though we did not identify an als3 mutant, the identification of only als6 in our
screen may also signify some importance with regards to attachment and “sensing” of
bacteria in the environment. It is possible that other members of the ALS gene family
could play some role in attachment and “sensing” of bacteria in the environment but due
to the nature of this screen, the reduction in gene expression of one copy of other ALS
genes may be insufficient to create a haploinsufficient phenotype. To our knowledge,
no implication of the ALS gene family in signal transduction has been suggested in the
literature. The ability of these proteins to “sense” bacteria would also add a new
functional role for these adhesion proteins with a relation to signal transduction. As with
CDR4 we did confirm our original screen results with heterozygous and homozygous
null mutants of ALS6 further lending credibility to its involvement in Candida-bacterial
interactions. However unlike CDR4 we did not see any induction of ALS6 in the
presence of the bacteria. Regardless, it is clear that ALS6 plays some role in either the
adherence to bacteria or “sensing” bacteria in the environment and is somehow able to
convey that response by inhibiting Candida filamentation.
We were quite surprised to identify multiple insertions within the RPS and RB2
regions of the MRS. In the original use of the haploinsufficiency screen by Uhl et al
[34], they also identified insertions within these regions from four clones that either
increased or decreased filamentation under their experimental conditions. They
identified one ORF they termed FGR6 (fungal growth regulator) within the RB2 region,
though as to its actual function nothing is currently known. There are eight copies of
this gene in the genome that all reside within the RB2 region of the MRS elements
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[37,55]. It has been suggested that mutations affecting the FGR6 family of genes
phenotypically are not believed to be due to haploinsufficiency but some type of
dominant regulatory mechanism [55]. Though we have no evidence, it is also possible
that insertions of the Tn7 elements into the MRS regions could locally destabilize a
region of a chromosome, inadvertently causing a chromosomal
translocation/rearrangement thereby affecting the observed phenotype in this screen.
The identification of 18 non-coding/unannotated transcripts also was unexpected.
These transcripts were previously identified using RNA-seq and gene tiling studies on
the C. albicans genome [39,40]. These non-coding or unannotated transcripts may
represent small protein coding genes with fewer than 90 amino acids or could possibly
be new types of regulatory RNAs that may represent an additional level of control on the
morphogenic process. Currently, little to nothing is known about the role of non-coding
transcripts or small ORFs below 90 amino acids and their role in C. albicans
morphogenesis. However, the idea that several of these transcripts could code for
regulatory RNAs is intriguing. None of the transcripts appear to be transcribed as
antisense with other known ORFs so it is possible that they could play a role in RNA
silencing. Nevertheless, there has been some controversy about whether RNA
silencing actually occurs in C. albicans. Initially, using cell extracts, it had been shown
that C. albicans does have a Dicer-like activity [56]. A second study demonstrated that
in vivo production of a dsRNA hairpin to interfere with the ADE2 gene resulted in no
observable gene silencing [57]. Furthermore, characterization of the DCR1 dicer gene
of C. albicans demonstrated that this activity is primarily associated with rRNA and and
snRNA processing [58]. So, it appears that if the transcripts we have reported here
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have any impact on RNA silencing of RNA pol II transcribed genes the mechanism is
likely unknown or does not exist in C. albicans.
This study has allowed us to develop the framework for future delineation of the
genetic and signaling events that occurs between Candida and bacteria. We postulate
that this genetic overlap with response to different bacterial species involves several
common pathways that C. albicans utilizes for communication. However, several
questions remain. For example, do the mutants we identified show a lack of response
to bacteria in their environment due to a single secreted bacterial metabolite or QS
molecule, or is it a combination of several molecules that exert the inhibitory action on
C. albicans? It is well documented that single molecules from bacteria can inhibit C.
albicans filamentation under laboratory conditions [11,12,14,16,17], but it is not well
understood if these molecules are present in the environment at all times, which could
indicate a combination of effectors may be required in the environment. Also, do the
mutants that we have identified in this study also play a role in C. albicans QS
regulation of filamentation or is that a separate phenomenon? We believe that it is likely
that C. albicans uses some of these genes to regulate its own QS response as it doesn’t
make sense that C. albicans would have developed separate molecular machinery to
respond to both types of stimuli. We hope to address these questions in future studies.
We believe that in understanding the mechanisms of action of both bacterial QSMs and
other metabolites on C. albicans biology may lead to development of novel ways to
control C. albicans growth in critically ill patients in addition to current antifungal
therapies.
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Abstract
Numerous organisms inhabit the human body living out a life of intimate relationships
and unique interactions. Among these interactions are those involving the opportunistic
polymorphic fungi, Candida albicans, with bacteria. The ability of C. albicans to control
morphology, communicate via quorum sensing, attach to numerous surfaces, and form
complex biofilms are all important virulence factors of this fungal pathogen. Research
within the last decade has highlighted numerous bacterially secreted molecules that can
influence the dimorphic transition of C. albicans, yet little is known about how these
interactions function at a genetic level. In the present study, we characterized the
involvement of two genes, CDR4 and ALS6, previously identified by our lab for their
involvement in Candida-bacterial interactions. Strains lacking either CDR4 or ALS6
have increased filamentation as compared to wild-type strains when grown in the
presence of the C. albicans quorum sensing molecule farnesol as well as several
bacterial molecules known to inhibit filamentation. CDR4 and ALS6 null strains have
increased adhesion and biofilm growth when grown in the presence of farnesol and
bacterial molecules. Our data indicates that both CDR4 and ALS6 are part of the
machinery that defines how C. albicans responds to not only its own quorum sensing
molecule, but also bacterial products it can encounter in the environment. Delineating
the roles of CDR4 and ALS6 regarding Candida-bacteria interactions may aid in the
understanding of polymicrobial infections as well as identify new targets for antifungal
development.
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Introduction
With the recent findings of the Human Microbiome Project the impact microorganisms
have on human health is only beginning to be appreciated. For the first time, we now
have a snapshot of what constitutes a “healthy” individual. However, little is understood
about how members of the human microbiota interact and govern their behavior within
and on the host [1-5]. With the number of microorganisms constituting the microbiome
in the trillions there undoubtedly are a multitude of interactions, influences, and
competitiveness for a small amount of space and resources. This includes the
interactions between bacteria and the polymorphic opportunistic fungus Candida
albicans. Indeed, C. albicans is part of the normal flora for about 75% of the human
population and is particularly dangerous when it transitions from a member of the
normal flora to an opportunistic pathogen [6]. Among the populations that are at
increased risk for C. albicans infections are those of extreme age (both the young and
the elderly), immune suppressed, patients undergoing cancer treatment, and those on
long term antibiotic use [7,8]. In the hospital setting, C. albicans is quickly emerging as
an important healthcare concern as it is the most common fungal pathogen, the fourth
most common pathogen in systemic infections, and exhibits an increase in resistance to
current antifungal treatments [9-11].
A distinguishing virulence factor of C. albicans is its unique ability to control
morphology ranging from budding yeast to pseudohyphae to invasive hyphal filaments.
While the yeast form governs attachment and dissemination, it is the hyphal form that is
associated with severe infections [12,13]. Morphological control is mediated in C.
albicans through quorum sensing (QS) by the quorum sensing molecule (QSM)
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farnesol, an isoprenoid alcohol [14]. This phenomenon works in a density dependent
manner and allows C. albicans to coordinate morphology in response to the surrounding
environment. In addition to QS, filamentation can be manipulated in C. albicans by a
number of physiological factors such as pH, temperature, media, nutrients, or serum
[15,16]. The ability of C. albicans to control morphology is imperative for survival,
particularly in the human body where it is constantly in competition with bacteria for
space and resources as well as fending off host immune responses.
Numerous physical and chemical interactions have been identified between C.
albicans and bacteria. Perhaps the most studied of the physical interactions is that of
Pseudomonas aeruginosa and C. albicans and the antagonistic relationship they share.
P. aeruginosa can bind to and kill the hyphal-filamentous form of C. albicans, but not the
yeast form [17]. Alternatively, Streptococcus gordonii and Staphylococcus epidermidis
appear to have the ability to attach to both the yeast and hyphal forms of C. albicans
[18,19]. More recently, research has focused on small molecules secreted by bacteria
that impact C. albicans morphology. Specific molecules or spent media from a variety
of bacteria including Lactobacillus, Streptococcus, Pseudomonas, and Burkholderia
have been shown to interrupt C. albicans ability to transition between morphological
forms and many times these small bacterial molecules cause C. albicans to become
locked into the yeast form [1,20-22]. Alternatively, S. gordonii, and bacterially derived
molecules, such as peptidoglycan, appear to enhance hyphal formation in C. albicans
[18,23]. These analogous and conflicting effects that bacteria exert on C. albicans
demonstrate the dynamic relationships involved in a shared environment in an attempt
to achieve a competitive advantage.
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Previously, our lab performed a large scale library screen to identify genes that
C. albicans utilizes to control filamentation in the presence of bacteria [24]. Two of
these genes, ALS6 and CDR4, have shown potential to play participating roles in this
process. In this study, we demonstrate the involvement of ALS6 and CDR4 in C.
albicans response to farnesol as well as bacterial molecules as it pertains to
morphogenesis, attachment, biofilm formation, and gene expression.
Methods
Strains, media, and growth condition. C. albicans strains were routinely cultured on
Yeast Peptone Dextrose (YPD) medium (20g dextrose, 20g peptone, 10g yeast extract,
20g bacto agar in 1 liter) at 30°C. C. albicans wild-type SC5314 [25], CDR4 deletion
strain (cdr4/cdr4) [26], and ALS6 deletion strain (als6/als6) [27] have previously
been described. In all subsequent experiments, C. albicans strains were inoculated into
YPD and grown overnight for 16 hours at 30°C with shaking (155 rpm). Cells were
harvested by centrifugation, washed twice with sterile ultrapure water, and inoculated
into Medium 199 (M199) (9.5g medium 199 with Earles salts, 18.7 Tris-HCl, 20g bacto
agar, pH 7.5 ,q.s. to 1L).
Liquid filamentation assay. Filamentation assays were performed as previously
described, but with minor alterations [28]. Briefly, prior to cell addition, trans,transfarnesol (Sigma), trans-2-decenoic acid (TCI America), indole (Sigma), N-3-oxododecanoyl-L-homoserine lactone (HSL) (Cayman), lipopolysaccharide (LPS) from E.
coli (Sigma), Competence Stimulating Peptide-1 (CSP1) from Streptococcus mitis
(Genscript), 1-dodecanol (Acros), phenazine (Acros), and pyocyanin (Cayman) were
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added to pre-warmed (37°C) M199 liquid media. Washed C. albicans cells were
inoculated (1 x 106 cells/mL) and incubated under hyphal inducing conditions (M199,
pH7.5, 37°C, 155 rpm) for two and a half hours. Aliquots were then examined
microscopically (400x) for cell morphology. For each experimental condition 300
cells/field were counted and results were reported as the average of triplicate
experiments in terms of the percent of total cells displaying hyphal morphology.
Cell attachment assay. The cell attachment assay was performed as previously
described with some modifications [29]. Briefly, 96 well plates were pre-coated with 5%
serum and incubated overnight at 4°C. Excess serum was then removed from the wells
and trans,trans-farnesol, trans-2-decenoic acid, indole, HSL, or LPS were diluted into
either methanol, water, or DMSO and added to pre-warmed (37°C) M199 media at
varying concentrations in the 96 well plates. Cells were inoculated at 1 x 10 5 cells/well
and plates were incubated at 37°C for 90 minutes to allow for attachment. Plates were
then washed with sterile dH2O, to remove non-bound cells. They were air dried, stained
with 100μL crystal violet, washed with dH2O after 10 minutes, treated with 033% acetic
acid to release the stain and transferred to a second plate where the absorbance
(600nm) was measured using a Turner Biosystems modulus microplate reader.
Attachment assays were carried out in three independent trials with each individual trial
carried out in triplicate.
Biofilm assay. The biofilm assay was carried out similarly to the attachment assay with
minor modifications [29]. Again, 96 well plates were pre-coated with 5% serum and
incubated overnight at 4°C. Excess serum was removed from the wells and strains
were inoculated (1x106 cells/mL) into pre-warmed M199 media, added to each well, and
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incubated at 37°C for 90 minutes to allow for attachment. The attached cells were then
washed to remove non-bound cells and fresh media containing trans,trans-farnesol,
trans-2-decenoic acid, indole, HSL, or LPS were added and the plates were incubated
for 48 hours at 37°C. Plates were then assayed as described above [30]. Biofilm
assays were carried out in three independent trials with each individual trial carried out
in triplicate.
Results and Discussion
In this study, we chose to examine two genes previously identified by our lab for their
role in Candida-bacterial interactions regarding the C. albicans virulence traits of
filamentation, attachment, and biofilm formation. The first gene, ALS6, belongs to a
family of cell surface glycoproteins that are associated with adhesion to surfaces [31].
The ALS1 and ALS3 family members have also been demonstrated to be involved in
Candida-bacterial interactions by mediating aggregation [32] and particularly in the
adherence of C. albicans to Staphylococcus aureus [33]. Deletion of ALS6 has been
shown to cause an increase in adhesion to human cells [27] so there is some question
as to the specific role of ALS6. This increase in adhesion by the als6-/- strain may
indicate that there is some sort of coordinated regulation within the ALS gene family for
adherence. It is entirely possible that since ALS6 is not a highly expressed protein it
may play a specialized role in the ALS gene family, possibly it functions to “see” and
“sense” the environment for contacts with bacterial and host cells rather than a direct
role in adherence. The second gene we examined, CDR4, belongs to a family of ABC
transporters [26]. While CDR1 and CDR2 are involved with C. albicans resistance to
fluconazole and transport of phospholipids [34], CDR4 does not appear to play a role in
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fluconazole resistance and the cellular function of CDR4 is unknown at this time [26]. In
regards to CDR4 involvement in polymicrobial interactions, co-cultures of Lactobacillus
rhamnosus or L. reuteri [35] with C. albicans causes a 2 to 3 fold increase in CDR4
expression. As these are Gram positive bacteria that produce peptide QSMs it is
possible that CDR4 induction is in relation to uptake of these peptide molecules. S.
aureus has been shown to regulate its QS response in a similar fashion using ABC
transporters in the import of secreted peptides [36], however, ABC transporters are
known to import and export a large variety of compounds into and out of the cell [37].
C. albicans cdr4-/- and als6-/- strains have increased filamentation in the
presence of farnesol and several bacterial molecules. We have previously identified
mutants of CDR4 and ALS6 that were able to filament in the presence of high levels of
bacteria. To determine the involvement of CDR4 and ALS6 in the response to farnesol,
bacterial QSMs, and other bacterial metabolites, SC5314 wild type and null strains were
grown in the presence of a panel of molecules known to affect morphogenesis.
SC5314, cdr4 -/-, and als6 -/- strains were grown under hyphal inducing conditions for
2.5 hours with or without the addition of CSP1, 1-dodecanol, trans,trans-farnesol, HSL,
indole, LPS, phenazine, pyocyanin, or trans-2-decenoic acid. We also performed this
assay with reconstituted heterozygous strains of CDR4 and ALS6, which exhibited
phenotypes identical to the homozygous nulls (data not shown). We chose these
compounds as they are known to be secreted into the environment by bacteria, with the
exception of farnesol, which is the QSM of C. albicans and 1-dodecanol. Dodecanol
has previously been used as a surrogate for HSL when inhibiting hyphal filamentation
[38]. However, it has been demonstrated that dodecanol exerts its effect on C. albicans
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differently than HSL [39]. We chose farnesol to determine if the mutant strains would
respond to the QSM. Using increasing amounts, we attempted to identify
concentrations of the various molecules that demonstrated a measureable effect, but
not completely inhibitory due to potential toxicity (Supplementary Figure 3.1). Figure
3.1A is a representation of the concentrations where a measureable effect was
observed on the cells by the molecules, but without toxicity. The addition of these
molecules did not alter growth rates and the solvents (methanol, water, or DMSO) used
to dilute the molecules had no significant effect on morphology (data not shown). Also,
solvents never constituted more than 1% of the total volume. Under control conditions,
after 2.5 hours 93% of the wild-type SC5314 strain cell population displayed the typical
hyphal-filamentous dominant morphology while cdr4 -/- and als6 -/- strains show similar
morphology to the wild-type SC5314 control with about 91% of cell populations
producing hyphae. Farnesol served as a control for filamentation with the wild-type
strain, but also as a test for determining whether the als6-/- and cdr4-/- strains respond
to the molecule. The addition of farnesol at 50µM, 150µM, and 300µM concentrations
greatly reduced wild-type SC5314 hyphal morphology populations to 32%, 15%, and
11% respectively. At 50µM, 150µM, and 300µM concentrations of farnesol, the cdr4-/strain had 57%, 40%, and 19% hyphal morphology while als6-/- had 56%, 30%, and
15% hyphal morphology, thus both deletion strains had significantly increased hyphal
morphology over wild-type SC5314 (Figure 3.1A and Supplementary Figure 3.1).
Figure 3.1B demonstrates the observed hyphal phenotypes of the cdr4-/- and als6-/clearly indicating they are refractory to the molecule and are involved in C. albicans QS
response. The cdr4-/- and als6-/- strains were refractory to a number of bacterial
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molecules as well. At 50µM and 200µM concentrations of HSL, cdr4-/- had significantly
more hyphal cells (79% and 15%) than wild type (65% and 9%) at both concentrations
while als6-/- (14%) only displayed increased hyphae over wild-type SC5314 at the
200μM concentration (Figure 3.1A and Supplementary Figure 3.1). At 1mM and
2mM concentrations of indole, cdr4-/- (81% and 65%) and als6-/- (81% and 72%)
strains were also able to produce more hyphae than wild-type SC5314 (72% and 56%),
however this was not enhanced above 2mM with almost all cells in all three strains
having yeast morphology at 4mM concentrations (Figures 3.1A and Supplementary
Figure 3.1). trans-2-decenoic acid required relatively small concentrations to observe
hyphal morphology population differences. The addition of 1µM of trans-2-decenoic
reduced SC5314 to near 54% hyphal morphology and 5µM greatly exacerbated this
effect to 19% hyphae. The cdr4-/- and als6-/- strains still retained the ability to produce
significantly more hyphal cells at 1µM, 69% and 63% respectively, and this was also
observed at 5µM with both cdr4-/- and als6-/- at around 30% hyphae. At 25 µM of
trans-2-decenoic acid concentrations all three strains produced negligible amounts of
hyphal cells (Figure 3.1A and Supplementary Figure 3.1). LPS has also been
demonstrated to inhibit filamentation of C. albicans. We observed that at 1ug/mL cdr4-/(47%) had the most refractory phenotype while the als6-/- strain (20%), surprisingly,
appeared to be more sensitive than the wild-type SC5314 (30%) with more yeast cell
phenotypes (Figure 3.1A and Supplementary Figure 3.1). Adding CSP1, phenazine,
and pyocyanin decreased the percentage of hyphal cells, but did so at similar and
insignificant levels when cdr4-/- and als6-/- strains were compared to wild-type SC5314,
indicating that the activity of these molecules is not dependent on ALS6 or CDR4.
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Interestingly, 1-dodecanol concentrations at or above 50µM, almost completely ablated
the ability of all three strains to produce hyphae indicating that response to dodecanol is
not through the same mechanism, but due to some other stress on the cells (Figure
3.1A and Supplementary Figure 3.1).
Of the molecules tested, the reduced response to trans,trans,-farnesol was the
greatest when comparing cdr4-/- and als6-/- deletion strains to the wild type control.
While the deletion strains did have fewer hyphal cells in the presence of exogenously
added trans,trans-farnesol, they still produced twice the number of hyphal cells as the
control. The addition of indole, trans-2-decenoic acid or HSL reduced hyphal cell
numbers in all strains, but the cdr4-/- and als6-/- deletion strains maintained increased
numbers of hyphal cells. This could indicate that there is a global signal-response
cascade that C. albicans utilizes in the control of morphogenesis in reaction to its own
QS molecule as well as bacterially secreted factors. Numerous bacterial molecules that
have been identified to inhibit C. albicans morphogenesis share similar carbon
backbone molecular structures to farnesol. HSL from P. aeruginosa 1 and varying forms
of decenoic acid from S. mutans, B. cenocepacia, and X. campestris [21,22,40] all
share structural similarities to farnesol and appear to inhibit hyphal morphogenesis.
The fact that the deletion strains in the presence of inhibitors did not restore hyphal cell
populations to control levels could indicate that CDR4 and ALS6 play participating or cofactor roles in the genetic pathway regarding small molecule regulation of
morphogenesis. It is also possible that CDR4 and ALS6 are not critical regulators of
this pathway and can be compensated in part by other genetic factors, but the fact that
deletion of these factors causes a significant increase in hyphal morphology cannot be
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disregarded. Perhaps the most interesting result of the filamentation assay was that
cdr4-/- and als6-/- were not responsive to farnesol and HSL, but were to dodecanol.
Dodecanol has been used in many publications as a substitute to HSL and as a control
in experiments as a hyphal formation inhibitor [1,38]. However, recent research has
shown that dodecanol acts along a different mechanism than that of farnesol and HSL
[39]. This could indicate, when evaluated with our results, that CDR4 and ALS6 act
along a separate signaling system and accounts for the increase in hyphal morphology
of the deletion strains to farnesol and HSL, but not dodecanol. It is important to note, of
the bacterial compounds tested, some did not produce significant differences between
the control and deletion strains. CSP1, phenazine, and pyocyanin reduced hyphal cell
numbers equally in both the wild-type control strain as well as the cdr4 and als6 deletion
strains. It is worth mentioning that the CSP1 used in this study is different from the
CSP1 used in the original paper identifying these peptides as inhibitors of
morphogenesis [41] which may explain the inability of it to elicit a reaction in the control
and mutant strains we tested.
Figure 3.1 (a) The effects of trans,trans-farnesol and bacterial molecules on
morphology of C. albicans SC5314 wild-type, cdr4-/-, and als6-/- strains. Strains were
grown under hyphal inducing conditions (pH7.5, 37°C, M199 media) for 2.5 hours with
or without the addition of bacterial molecules: competence stimulating peptide-1 (CSP),
1-dodecanol (DOD), trans,trans-farnesol (FRN), 3-oxo-C12-homoserine lactone (HSL),
indole (IND), lipopolysaccharide (LPS), phenazine (PHN), pyocyanin (PYO), or trans-2decenoic acid (TDA). Morphology was determined microscopically by counting 300
cells and expressed as the percentage of cells displaying hyphal morphology. Asterisk
denotes statistical significance (p < 0.05) compared to matched SC5314 wild-type
control as determined by student’s t-test. The mean and standard deviation of triplicate
trials are shown. (b) Effects of trans,trans-farnesol on morphology of C. albicans wildtype, cdr4-/- and als6-/- strains. Strains were inoculated (1x106 cells/mL) into hyphal
promoting conditions (ph7.5, 37°C, M199 media) with or without the addition of 150µM
of trans,trans-farnesol. After 2.5 hours morphology was examined. (Top panel) wildtype SC5314 control, (Middle panel) cdr4-/- deletion strain, (Lower panel) als6-/deletion strain.
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C. albicans cdr4-/- and als6-/- cells have increased attachment and biofilm
formation in the presence of farnesol and known bacterial inhibitors. Farnesol has
been known to inhibit or reduce the ability of C. albicans to adhere to abiotic surfaces
[42]. Taking the molecules that were found to be significant in the filamentation assay,
the next step was to measure the ability of C. albicans to adhere to polystyrene surface
in the presence of trans,trans-farnesol, indole, trans-2-decenoic acid, HSL, or LPS. C.
albicans SC5314, cdr4-/-, and als6-/- strains were inoculated into M199 with the addition
of farnesol or bacterial molecules and incubated under hyphal inducing conditions for
1.5 hours to allow for attachment. The effects of increasing concentrations of these
molecules on C. albicans wild type and null strains in regards to attachment are shown
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in Figure 3.2 and Supplementary Figure 3.2. Since values were obtained in respect
to optical density the untreated SC5314 control was designated as 100% attachment
and all other percent values were determined in relation to this optical density value.
SC5314, cdr4-/-, and als6-/- strains, without added molecules, served as a control
baseline and all three strains had near equal ability to attach to the 96 well plates. The
addition of trans,trans-farnesol reduced the attachment ability of all three strains, but
significant differences were not found until the concentration of farnesol exceeded
150µM. At 300µM concentrations of trans,trans-farnesol, both cdr4-/- and als6-/- strains
were able to significantly attach with a higher percentage, 77% and 83%, than that of
the SC5314 control which only had about 69% of attached cells (Figure 3.2). HSL, at
both 50µM and 200µM, caused a decrease in wild-type SC5314 attachment, while both
cdr4-/- and als6-/-, surprisingly, had equal or greater attachment than that of the wildtype SC5314 as well as near the levels of the molecule free media only controls (Figure
3.2). Indole, at all concentrations, decreased attachment for all three strains with no
significant difference in their ability to adhere to polystyrene (Figure 3.2). LPS had
minimal effect on all three strains with each retaining their ability to attach near the
levels of the untreated controls (Figure 3.2). Finally, trans-2-decenoic acid, at the
highest concentration of 25µM, resulted in the SC5314 having about 63% of the
attached cells while cdr4-/- and als6-/- had 78% and 85% respectively (Figure 3.2).
These results indicate that trans,trans-farnesol, HSL, trans-2-decenoic acid do not
dramatically inhibit the ability of cdr4-/- and als6-/- strains to adhere to polystyrene.
However, the reduction in adherence is slightly above wild type suggesting that the
initial stage of biofilm adherence is minimally compromised by these molecules. The
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similar molecular structure of trans, trans-farnesol, trans-2-decenoic acid, and HSL
could indicate that attachment to abiotic surfaces is impacted by Cdr4p and Als6p in
response to molecules with the shared 12 carbon backbones and not the lipid
polysaccharide structure of LPS or the aromatic structure of indole.

Figure 3.2. Effects of farnesol and bacterial molecules on attachment of C.
albicans SC5314 wild-type, cdr4-/-, and als6-/-strains to abiotic surfaces.
Strains were grown in 96 well polystyrene plates under hyphal inducing conditions
(pH7.5, 37°C, M199 media) for 1.5 hours with or without the addition of:
trans,trans-farnesol (FRN), 3-oxo-C12-homoserine lactone (HSL), indole (IND),
lipopolysaccharide (LPS), and trans-2-decenoic acid (TDA). Attachment was
determined by crystal violet staining and quantified by absorbance. Asterisk
denotes statistical significance (p<0.05) compared to matched SC5314 wild-type
control as determined by student’s t-test. Control SC5314 without added bacterial
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molecules represents 100% attachment and all other values are determined in
proportion to this value. Mean percentage and standard deviation are shown.
Each condition was performed in triplicate and is the result of three independent
trials.

After determining the effects on attachment by trans,trans-farnesol, indole, trans-2decenoic acid, HSL, and LPS, we tested the ability of cdr4-/- and als6-/- strains to form
biofilms in the presence of these molecules. The effect of increasing concentrations of
these molecules on C. albicans wild type and null strains in regards to biofilm growth
are shown in Figure 3.3 and Supplementary Figure 3.3. Again, because values were
obtained in respect to optical density, the untreated SC5314 control was designated as
100% biofilm formation and all other percent values were compared in relation to this
optical density value. All three strains had near equal ability to form dense biofilms
under control conditions by 48 hours. No statistical difference was found between the
wild-type SC5314 control and cdr4-/- and als6-/- strains at trans,trans-farnesol
concentrations of 50 and 150µM. However, at the 300µM concentration of trans,transfarnesol there was an increase in total biofilm mass by the cdr4-/- (81%)and als6-/(80%) strains over wild-type SC5314 (65%) (Figure 3.3). At the 200µM concentration
of HSL wild-type SC5314 was reduced to 85%% while cdr4-/- (98%) and als6-/- (95%)
had significantly more biofilm mass which were near the untreated control levels.
(Figure 3.3). Indole added at the highest concentration, 4mM, was able to suppress
biofilm formation of wild-type SC5314 to 77% and only als6-/- (83%) was able to
significantly increase biofilm formation over the wild-type SC5314 control (Figure 3.3).
LPS minimally reduced biofilm mass of all three strains, but cdr4-/- (98%) and als6-/(98%) had an increased biofilm mass over wild-type SC5314 (91%) (Figure 3.3).
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Lastly, there was no statistical difference among the three strains when trans-2
decenoic acid was added with all three strains having equal reduction in biofilm mass
(Figure 3.3).

Figure 3.3. Effects of farnesol and bacterial molecules on biofilm formation of C.
albicans SC5314 wild-type, cdr4-/-, and als6-/- strains. Strains were grown in 96
well polystyrene plates under hyphal inducing conditions (pH7.5, 37°C, M199
media) for 1.5 hours then fresh media was added with or without the addition of:
trans,trans-farnesol (FRN), 3-oxo-C12 homoserine lactone (HSL), indole (IND),
lipopolysaccharide (LPS), and trans-2-decenoic acid (TDA). Biofilm formation was
determined by crystal violet staining and quantified by absorbance. Asterisk
denotes statistical significance (p<0.05) compared to matched SC5314 wild-type
control as determined by student’s t-test. Control SC5314 without added bacterial
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molecules represents 100% biofilm formation and all other values are normalized
to this value. Mean percentage and standard deviation of triplicate trials are
shown.

In both the attachment and biofilm assays, with a few exceptions, only the highest
concentrations of trans, trans-farnesol and bacterial molecules were able to elicit a
statistically significant difference. This result is supported by a previous study that
looked at attachment time, inhibition of biofilm formation, and increasing concentrations
of farnesol [42]. This earlier study determined that high concentrations of farnesol
(300μM) were required to inhibit C. albicans biofilm formation and that attachment time
also played a factor in this process [42]. This is likely due to the community lifestyle
where C. albicans biofilms have been shown to be up to 2000 times more resistant to
antifungals [43]. With the exception of farnesol, none of the molecules tested were able
to dramatically decrease attachment or biofilm formation among any of the strains
tested. This may be the result of two factors. First, due to the complexity that
communities of C. albicans encompass, it may be that higher concentrations are
required to produce a reduction in attachment and biofilm formation. It has been well
documented that planktonic cells are more susceptible to antifungals than stationary
cells [43]. Secondly, it has been shown that C. albicans cells locked into the yeast form
still retain the ability, albeit at a reduced capacity, to attach and form biofilms [44]. The
study of C. albicans in the context of polymicrobial interactions is definitely one with
numerous factors to consider. In a series of studies on the effect of LPS on C. albicans
attachment and biofilm growth, Bandara et al. [45-47] established that the bacterial
species the LPS was derived from, the amount of time, the concentration of LPS, the
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species of Candida, and even a Candida strain dependency were all factors that
influenced the increase, decrease, or no effect on attachment and formation of Candida
biofilms.
Conclusions
Overall, we have begun to explore the impact that C. albicans genes play in Candidabacterial interactions and their potential role in C. albicans quorum sensing. Though
this has been a limited study with two genes of interest, there are several that we
identified previously [24] that remain to be characterized in the future. Furthermore, this
lays the groundwork into deciphering C. albicans-bacterial interactions at the genetic
level. For example, can we alter the bacterial molecules that inhibit C. albicans
filamentation and use them for new antifungal therapies alone or in addition to current
treatments? Further work needs to establish the mechanisms of action that bacterial
molecules have on C. albicans as well as further characterization of their production
when C. albicans and different bacteria are present in co-culture.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTION
Use of Genetic Library Screening in Candida-Bacterial Interactions
The use of genetic library screens in microbiological research has been
instrumental in determining numerous attributes of microorganisms and C. albicans is
no exception. More specifically, the use of a Tn7 transposon as an insertional mutagen
to identify genes instrumental in specific functions of C. albicans is becoming more
prevalent as a research tool. The original Tn7 library implemented in our research was
derived from a study that screened for genes involved in C. albicans filamentous growth
(Uhl et al. 2003). Tn7 library screenings have also been used to identify genes involved
in the C. albicans RAM signaling pathways of filamentation (Bharucha et al. 2011), and
haploinsufficiency has aided in observable changes in phenotypes for other studies
including drug susceptibility targets (Oh et al. 2010). The results from our study
demonstrate that a Tn7 transposon insertion library can successfully be used to identify
genetic elements involved in Candida-bacterial interactions.
Defining Signaling Pathways in Candida-Bacterial Interactions
The signaling cascade of events involved in C. albicans regulation of morphology
in response to bacteria and bacterially derived molecules is relatively unknown.
Presumably, these signaling pathways could coincide with some of the same elements
that control morphology as directed by the autoregulatory molecule farnesol. However,
given the diverse array of bacteria that C. albicans contacts within the shared habitat of
the human body a number of questions arise: 1) Are the genetic pathways that control
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morphology the same, share components of, or completely different between farnesol
response and bacterial response? 2) Are there global signaling pathways in C. albicans
in response to all bacteria or are they specialized? For example, do Gram-positive
bacteria use the same pathways as Gram-negative or entirely different pathways? 3)
Do those bacteria that have antagonistic relationships with C. albicans activate separate
pathways than those that share mutualistic or symbiotic relationships? 4) Are there
human host factors that influence or exacerbate these Candida-bacterial interactions?
5) How do these polymicrobial interactions alter the host immune response? Bacteria
exposure elicits a different immune response from that of Candida, and evidence exists
showing that combined Candida-bacterial exposure causes a host response directed at
one microorganism while the other may benefit from a less specific host response
(Allard et al. 2009). Polymicrobial exposure also causes distinct proinflammatory
responses compared to monomicrobial exposure as well as numerous documented
examples of increased mortality of coinfection where single species infection cause no
mortality (Carlson 1982; Klaerner et al. 1997; Peters and Noverr 2013).
Polymorphism as a Target for C. albicans Treatments
The interest of C. albicans polymorphism as a virulence trait and the role it plays
in pathogenesis is evident in the escalation of research involving the understanding of
the regulation of this shift, as well as investigation of therapeutics aimed at inhibiting this
trait. Understandably, development of pharmological interventions that could block this
transition is very attractive in that they could hinder Candida overgrowth, reduce
invasiveness, and diminish biofilm capacity. The importance of the 2 dominant
morphologies, yeast and hyphae, and their role in infection has been and continues to
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be ardently debated. Typically, yeast cells are associated with moderate attachment
ability and little to no invasiveness and host damage. Thus, yeast cells are associated
with initial attachment and dissemination. Alternatively, the hyphal form is believed to
have strong adhesive ability, invasiveness, increased damage, dissemination across
epithelial cells, and host immune evasion. While hyphal cells can be found in tissue,
there are reports that yeast cells can be found as well. Likewise, commensal C.
albicans are believed to be of yeast morphology, while the invasive hyphae are believed
to be involved in infections (Cheng et al. 2012). In reality, it is the ability to express both
morphologies that leads to full virulence. This is evident by 2 lines of evidence. First,
biofilms of C. albicans that are locked into either morphological form are severely
attenuated in their growth and drug resistance (Baillie and Douglas 1999). Second,
Candida locked into either morphological form are avirulent (Baillie and Douglas 1999).
Inhibiting polymorphism has been successfully used to treat Candidiasis in mouse
models (Ramage et al. 2002). Targeting the virulence factors of C. albicans may prove
more effective and sustainable as a treatment option given that C. albicans cells remain
viable, thus, there are limited selective pressures that would promote or favor drug
resistance. However, only in obtaining a thorough understanding of the signaling
events and genetic controls of polymorphism and QS combined will there be effective
treatment options based on such.
Quorum Sensing as a Target for C. albicans Treatment
Farnesol appears to be a tempting mode of treating Candida infections as it
governs the morphogenic transition. However, the application of farnesol in vivo has
garnered mixed results. Farnesol has been shown in mouse models to provide
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protection in oral candidiasis (Hisajima et al. 2008). This has also been observed in
human cells where farnesol exposure increased host immune response as well as
inhibited morphogenesis (Saidi et al. 2006; Décanis et al. 2009). The effects of farnesol
on systemic candidiasis were less favorable as a treatment option. Mice in a systemic
candidiasis model that were administered farnesol had increased mortality and there
was an inhibition of immune function that made the mice more vulnerable to candidiasis
(Navarathna et al. 2007). In vitro, farnesol is able to inhibit Candida biofilms as well as
cause apoptosis in Candida cells (Ramage et al. 2002; Shirtliff et al. 2009).
Quorum Sensing as a Method of Controlling Polymicrobial Infections
Locking Candida into the yeast form could prove valuable in combating
polymicrobial infections. It is well documented that a number of bacteria preferentially
associate with the hyphae of C. albicans and in some instances are unable to attach to
the yeast form (Hogan and Kolter 2002; Tampakakis et al. 2009). Locking C. albicans
into the yeast form could reduce the colonization of bacteria and possibly diminish the
development of mixed species biofilms. Again, locking C. albicans into the yeast form
produces minimal biofilms that would also reduce the ability of Candida-bacterial
biofilms from becoming established (Baillie and Douglas 1999). Candida-bacterial
biofilms are more resistant to antifungals and antibiotics so this would reduce the
burden of long courses of treatment with high concentrations of antimicrobials, lead to
fewer instances of polymicrobial biofilms, as well as reducing the reservoir of infection.
In vitro testing of farnesol on bacterial biofilms has shown to work synergistically with
antibiotics, inhibit biofilm formation, and compromise cell integrity (Meiller et al. 2006;
Cugini et al. 2007; Peleg et al. 2008). Farnesol appears to have the ability to inhibit
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both the attachment and maturation phases of bacterial biofilm growth as well as
reduction in preformed biofilms and causes biofilm detachment (Unnanuntana et al.
2009; Cerca et al. 2012).
The targeting of C. albicans virulence factors, such as polymorphism, holds great
potential in both the treatment of monospecies C. albicans infections as well as
polyspecies Candida-bacterial infections. With the increases in drug resistance, the
large percentage of polymicrobial infections affecting patients, and the limited number of
antifungals there is a recognizable need for new applications to combat C. albicans. A
significant key to advancing new therapeutics may be the molecules and metabolites
microorganisms use, such as QS, during their own plight to survive when challenged by
other microorganisms.
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APPENDICIES

Supplemental Data

Supplementary Table 2.1.
Systematic
Standard
Name
Name
orf19.10
ALK8
orf19.23
RTA3
orf19.344
------orf19.346
------orf19.470*
------orf19.511
------orf19.517
HAP31
orf19.526
NHP2
orf19.536
------orf19.860
BMT8
orf19.978
BDF1
orf19.999
GCA2
orf19.1040
MAD2
orf19.1110
------orf19.1201
------orf19.1368
------orf19.1401
EAP1
orf19.1523
FMO1
orf19.1693
CAS4
orf19.1728
------orf19.1759
PHO23
orf19.1911
PGA52
orf19.1941
NUF2
orf19.1996* CHA1
orf19.2038
------orf19.2081
POM152
orf19.2106
------orf19.2114
------orf19.2138
ILS1
orf19.2290
TOR1
orf19.2356
CRZ2
orf19.2417* SMC5
orf19.2423
ZCF11
orf19.2495
GSL1
orf19.2524
MGE1
orf19.2579
------orf19.2929
GSC1

Genetic elements identified from the C. albicans Tn7 insertion library screen
Tn7
Library
Predicted/Known
Predicted/Known
Location
Number
Biological Function
Protein Localization
ORF
166a9
Enzymatic activity
Endoplasmic Reticulum
5’ of ORF
4g8
Transport
Membrane
3’ of ORF
181a2
Unknown
Unknown
3’ of ORF
158c12
Enzymatic activity
Cytoplasm
ORF
133f7
Transcription
DNA binding complex
5’ of ORF
125c6
Enzymatic activity
Cytoplasm
5’ of ORF
159f4
Transcription
DNA binding complex
ORF
128d3
RNA processing
RNA binding complex
3’ of ORF
122e7
Transcription
DNA binding complex
3’ of ORF
129a8
Cell wall associated
Unknown
5’ of ORF
177c11
Transcription
Chromosome
ORF
133d12
Enzymatic activity
Endoplasmic Reticulum
ORF
125h1
Cell cycle
Chromosome
5’ of ORF
138d11
Enzymatic activity
Cytoplasm
5’ of ORF
184e2
RNA processing
Mitochondria
3’ of ORF
75b1
Unknown
Unknown
5’ of ORF
42f9
Adhesion
Membrane
ORF
180c12
Enzymatic activity
Unknown
ORF
154d11
Signaling
Cell tip
ORF
162f11
Unknown
Unknown
ORF
134b7
Transcription
RNA binding complex
ORF
134c6
Cell wall associated
Membrane
5’ of ORF
135b3
Cell cycle
Chromosome
ORF
70a7
Amino acid synthesis
Unknown
3’ of ORF
178a8
Unknown
Unknown
ORF
75d8
Transport
Membrane
ORF
160b6
Unknown
Unknown
ORF
134g2
Enzymatic activity
Nucleus
ORF
49c11
RNA processing
Cytosol
ORF
98f7
Signaling
TOR complex
ORF
74e11
Transcription
Intracellular
ORF
61e7
DNA repair
Nucleus
ORF
149b7
Transcription
Nucleus
ORF
93h4
Cell wall associated
Membrane
5’ of ORF
156f2
Transport
Mitochondria
ORF
184c4
DNA binding
Chromosome
3’ of ORF
156b8
Cell wall associated
Membrane
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orf19.2982
orf19.2989
orf19.3001
orf19.3087.2
orf19.3100
orf19.3124
orf19.3394
orf19.3519
orf19.3643
orf19.3730
orf19.3767
orf19.3791
orf19.4018*
orf19.4023
orf19.4054
orf19.4086
orf19.4099
orf19.4112
orf19.4119
orf19.4176
orf19.4246
orf19.4261
orf19.4263
orf19.4412
orf19.4610
orf19.5076
orf19.5101*
orf19.5144
orf19.5169*
orf19.5212
orf19.5407*
orf19.5485
orf19.5506
orf19.5519
orf19.5665
orf19.5799
orf19.5813
orf19.5897
orf19.5902*
orf19.5938
orf19.6082
orf19.6323
orf19.6488*
orf19.6592
orf19.6722*
orf19.6736
orf19.6747
orf19.6785

------GOR1
TEM1
------------------------SUA72
------------------FGR10
------MRP2
CTA24
------ECM17
------SPO72
------------TIF5
------------------CDR4
CCR4
PGA28
------------SOF1
MEC3
PLC1
GCV1
------------------------RAS2
SEN1
------HPA2
------------------------------RPS12

ORF
3’ of ORF
ORF
ORF
3’ of ORF
ORF
ORF
ORF
ORF
ORF
ORF
ORF
ORF
ORF
ORF
3’ of ORF
ORF
3’ of ORF
ORF
ORF
ORF
5’ of ORF
ORF
ORF
ORF
5’ of ORF
5’ of ORF
5’ of ORF
5’ of ORF
ORF
ORF
ORF
ORF
5’ of ORF
ORF
ORF
3’ of ORF
5’ of ORF
ORF
ORF
ORF
5’ of ORF
ORF
3’ of ORF
ORF
5’ of ORF
ORF
ORF

69g10
96g2
134c1
161e5
156f1
131a2
134d10
145c6
131b1
120c7
158c10
143h2
116b7
143d4
125c9
126g4
95b6
135c1
175e7
147h9
68d3
127f6
173g2
120d11
161g5
35d10
133d6
97h8
94b8
81c7
68e6
134f5
134g3
162d1
134d9
170c3
125h3
168h5
109b6
134b8
175a5
88a4
72d12
176f2
78e8
78g8
175c8
189h2

Autophagy
Enzymatic activity
Cell cycle
Unknown
Unknown
RNA binding
Unknown
Transcription
Unknown
Protein processing
Protein processing
Proteolysis
RNA binding
Translation
Transcription
Protein processing
Amino acid synthesis
Enzymatic activity
Autophagy
Translation
Enzymatic activity
Translation
Unknown
DNA repair
Proteolysis
Transport
Transcription
Adhesion
Enzymatic activity
Protein processing
Ribosomal associated
DNA repair
Enzymatic activity
Enzymatic activity
Enzymatic activity
Unknown
Adhesion
Unknown
Signaling
RNA processing
Protein processing
Amino acid synthesis
Unknown
Transport
DNA repair
RNA repair
Transport
Ribosomal associated
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Unknown
Nucleus
Spindle pole body
Unknown
Unknown
Ribosome
Membrane
Unknown
Intracellular
Endoplasmic Reticulum
Golgi
Cytosol
Ribosome
Ribosome
Unknown
Cytoplasm
Cytosol
Cytosol
Membrane
Ribosome
Unknown
Ribosome
Unknown
Chromatin
Unknown
Membrane
DNA binding complex
Cell surface
Nucleus
Unknown
Ribosome
DNA binding complex
Cytoplasm
Mitochondria
Unknown
Cytoplasm
Nucleus
Cytosol
Membrane
RNA binding complex
Endoplasmic Reticulum
Nucleus
Unknown
Membrane
Cytosol
Mitochondria
Cytoplasm
Ribosome

orf19.6931
------ORF
70d10
RNA processing
RNA binding complex
orf19.6968* ------ORF
78g11
Unknown
Unknown
orf19.6987
DNM1
ORF
76a4
Protein processing
Mitochondria
orf19.7085
------3’ of ORF
176h6
Unknown
Unknown
orf19.7108
RPS18
3’ of ORF
187a10
Ribosomal associated Ribosome
orf19.7130
------ORF
125h4
Unknown
Unknown
orf19.7152
------5’ of ORF
185g12
Enzymatic activity
Mitochondria
orf19.7232
IRR1
3’ of ORF
94h8
Cell cycle
Nucleus
orf19.7301
------ORF
134d4
DNA binding
Unknown
orf19.7313
SSU1
5’ of ORF
168e11
Transport
Membrane
orf19.7342
AXL1
ORF
169d5
Proteolysis
Unknown
orf19.7358
------3’ of ORF
98d10
Protein processing
Mitochondria
orf19.7413
MMS21
5’ of ORF
176a10
DNA repair
DNA binding complex
orf19.7414* ALS6
5’ of ORF
49b8
Adhesion
Cell surface
orf19.7483
CRM1
ORF
149a8
Transport
Nucleus
orf19.7512
------ORF
131a3
Enzymatic activity
Unknown
orf19.7565
GNP3
ORF
99e9
Transport
Membrane
orf19.7567
------SPT7ORF
156e4
Unknown
Unknown
orf19.7572*
ORF
42h5
Transcription
Mitochondria
orf19.7579
FGR34
ORF
151a9
Unknown
Unknown
orf19.7657
POP3
ORF
90c8
RNA processing
RNA binding complex
orf19.7667* IAH1
5’ of ORF
131c7
Enzymatic activity
Cytoplasm
*denotes gene was identified in multiple candidates. Library numbers designate the plate number and
well number location of the candidate strain so that, if requested, individual candidates can be located.
Supplementary Table 2.2.
Major repeat sequence
MRS-R
MRS-1
MRS-2
MRS-4
MRS-6
MRS-7a
MRS-7b

Major repeat sequences identified from the C. albicans Tn7 library screen
Library number
71a3, 72f5
71c7, 76a5, 134c9, 134h11, 161a10
56a9, 70a3, 81a4, 81f9, 120h2, 124g9, 129f3, 132c7, 133b6, 134a7, 134b3,
134c10, 136f9, 142e7, 143d10, 151b11, 163a4, 165d11
113f8, 123e10, 133g9, 134e9, 165e11
133c5, 119g3, 144g9
42f11, 124d4, 124g12, 138d12
71b11, 176g8

Supplementary Table 2.3. Non-coding/unannotated transcripts identified in C. albicans library screen
Transcript name
Reference
Library number
Novel-Ca21chrR-009
Bruno et al.
145c8
Novel-Ca21chrR-023
Bruno et al.
134b12
Novel-Ca21chrR-093*
Bruno et al.
12e3
Novel-Ca21chrR-094
Bruno et al.
75e5
Novel-Ca21chrR-100
Bruno et al.
182c1
Novel-Ca21chr2-037
Bruno et al.
134g1
Novel-Ca21chr7-001
Bruno et al.
148b5
TFRW255
Sellam et al.
135b6
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TF1W4
Sellam et al.
TF1W160
Sellam et al.
TF3C2
Sellam et al.
TF3C162
Sellam et al.
TF4C158*
Sellam et al.
TF5C101
Sellam et al.
TF5W116
Sellam et al.
TF5W130
Sellam et al.
TF7C126
Sellam et al.
TF7W6
Sellam et al.
*denotes transcript was identified in multiple candidates
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159e10
98b5
61e3
183h1
134f6
76f10
134c3
166e9
95h6
88d10

Supplementary Figure 2.1. Phenotypes observed when SC5314, library
transposon candidates, heterozygous and homozygous deletion strains grown in
liquid culture (37°C) with bacteria or spent media. A) C. albicans strains with M199
filamentation control and coculture with E. coli, P. aeruginosa, and S. aureus.
Magnification 400x; B) C. albicans strains with M199 filamentation control and culture in
spent media E. coli, P. aeruginosa, and S. aureus. Magnification 400x.

A.
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B.
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Supplementary Figure 2.2. C. albicans CDR4 gene expression when cocultured with
a media only control, E. coli, P. aeruginosa, or S. aureus. ENO1 control is also shown.
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Supplementary Figure 3.1. Individual graphs of SC5314 wild type, cdr4-/-, and als6-/- cell
morphology in the presence of varying concentrations: (A) competence stimulating peptide-1
(CSP1), (B) 1-dodecanol, (C)trans,trans-farnesol, (D) 3-oxo-C12-homoserine lactone (HSL), (E)
indole, (F) lipopolysaccharide (LPS), (G) phenazine, (H) pyocyanin, and (I) trans-2-decenoic acid
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Supplementary Figure 3.2. Individual graphs of SC5314, cdr4-/-, and als6-/- attachment in the
presence of varying concentrations: (A) trans,trans-farnesol, (B) 3-oxo-C12-homoserine lactone
(HSL) , (C) indole, (D) lipopolysaccharide (LPS) , and (E) trans-2-decenoic acid.
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Supplementary Figure 3.3. Individual graphs of SC5314, cdr4-/-, and als6-/- biofilm formation
in the presence of varying concentrations: : (A) trans,trans-farnesol, (B) 3-oxo-C12-homoserine
lactone (HSL) , (C) indole, (D) lipopolysaccharide (LPS) , and (E) trans-2-decenoic acid.
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